<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_BDtzW3W">Global evolution of inflammatory bowel disease across epidemiologic stages</title>
				<funder>
					<orgName type="full">Astellas</orgName>
				</funder>
				<funder>
					<orgName type="full">Fresenius Kabi</orgName>
				</funder>
				<funder>
					<orgName type="full">Apsen</orgName>
				</funder>
				<funder>
					<orgName type="full">AstraZeneca</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004325</idno>
				</funder>
				<funder>
					<orgName type="full">Ferring Pharmaceuticals</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100004914</idno>
				</funder>
				<funder ref="#_uxN898m">
					<orgName type="full">Leona M. and Harry B. Helmsley Charitable Trust</orgName>
				</funder>
				<funder>
					<orgName type="full">Biogen</orgName>
				</funder>
				<funder>
					<orgName type="full">Celgene</orgName>
				</funder>
				<funder>
					<orgName type="full">Mylan</orgName>
				</funder>
				<funder>
					<orgName type="full">Pendopharm</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100024058</idno>
				</funder>
				<funder>
					<orgName type="full">Bristoll Myers Squibb</orgName>
				</funder>
				<funder>
					<orgName type="full">Sublimity Therapeutics</orgName>
				</funder>
				<funder>
					<orgName type="full">Protagonist Therapeutics</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100020154</idno>
				</funder>
				<funder>
					<orgName type="full">Astra Zeneca</orgName>
				</funder>
				<funder>
					<orgName type="full">InnoHK</orgName>
				</funder>
				<funder>
					<orgName type="full">Progenity</orgName>
				</funder>
				<funder>
					<orgName type="full">Thermo Fisher Scientific</orgName>
					<orgName type="abbreviated">TMO</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100011033</idno>
				</funder>
				<funder ref="#_uFWGGWD">
					<orgName type="full">Canadian Institutes of Health Research</orgName>
					<orgName type="abbreviated">IRSC</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100000024</idno>
				</funder>
				<funder>
					<orgName type="full">Biofermin</orgName>
				</funder>
				<funder>
					<orgName type="full">Pandion Pharma</orgName>
				</funder>
				<funder>
					<orgName type="full">UCB</orgName>
				</funder>
				<funder>
					<orgName type="full">Olympus</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100009734</idno>
				</funder>
				<funder>
					<orgName type="full">Lilly</orgName>
				</funder>
				<funder>
					<orgName type="full">Alvotech</orgName>
				</funder>
				<funder>
					<orgName type="full">Celltrion</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100018592</idno>
				</funder>
				<funder>
					<orgName type="full">Cosmos Pharmaceuticals</orgName>
				</funder>
				<funder>
					<orgName type="full">Sandoz</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100011218</idno>
				</funder>
				<funder>
					<orgName type="full">Gilead</orgName>
				</funder>
				<funder>
					<orgName type="full">Excelsior Biopharma</orgName>
				</funder>
				<funder>
					<orgName type="full">Glaxo-Smith Kline</orgName>
				</funder>
				<funder>
					<orgName type="full">Bristol-Myers Squibb</orgName>
				</funder>
				<funder>
					<orgName type="full">Theravance</orgName>
				</funder>
				<funder>
					<orgName type="full">JAMP Bio</orgName>
				</funder>
				<funder>
					<orgName type="full">Celgene/Receptos</orgName>
				</funder>
				<funder>
					<orgName type="full">Novartis</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004336</idno>
				</funder>
				<funder>
					<orgName type="full">Iterative Health</orgName>
				</funder>
				<funder>
					<orgName type="full">AbbVie</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100006483</idno>
				</funder>
				<funder>
					<orgName type="full">Mitsubishi Tanabe Pharma</orgName>
				</funder>
				<funder ref="#_KQ5fNcp">
					<orgName type="full">Research Grants Council-Research Impact Fund</orgName>
				</funder>
				<funder>
					<orgName type="full">Arena</orgName>
				</funder>
				<funder>
					<orgName type="full">International Organization for the study Inflammatory Bowel Disease</orgName>
					<orgName type="abbreviated">IOIBD</orgName>
				</funder>
				<funder>
					<orgName type="full">Elan</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100003037</idno>
				</funder>
				<funder>
					<orgName type="full">Tillotts Pharma</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100012276</idno>
				</funder>
				<funder>
					<orgName type="full">Boehringer Ingelheim</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100008349</idno>
				</funder>
				<funder>
					<orgName type="full">Gilead Sciences</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100005564</idno>
				</funder>
				<funder>
					<orgName type="full">Otsuka</orgName>
				</funder>
				<funder>
					<orgName type="full">Sanofi</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004339</idno>
				</funder>
				<funder>
					<orgName type="full">Organon</orgName>
				</funder>
				<funder>
					<orgName type="full">Roche</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004337</idno>
				</funder>
				<funder>
					<orgName type="full">Menarini</orgName>
				</funder>
				<funder>
					<orgName type="full">Shaare Zedek Medical Center, Hospital for Sick Children</orgName>
				</funder>
				<funder>
					<orgName type="full">Oppilan Pharma</orgName>
				</funder>
				<funder>
					<orgName type="full">Genentech</orgName>
				</funder>
				<funder>
					<orgName type="full">Gossamer Bio</orgName>
				</funder>
				<funder>
					<orgName type="full">Janssen</orgName>
				</funder>
				<funder>
					<orgName type="full">Shire</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100007343</idno>
				</funder>
				<funder>
					<orgName type="full">GlaxoSmithKline</orgName>
					<orgName type="abbreviated">GSK</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004330</idno>
				</funder>
				<funder>
					<orgName type="full">Eli Lilly</orgName>
				</funder>
				<funder>
					<orgName type="full">BMS</orgName>
				</funder>
				<funder>
					<orgName type="full">Government of Hong Kong, Special Administrative Region of the People&apos;s Republic of China</orgName>
				</funder>
				<funder ref="#_Qftf5u9">
					<orgName type="full">New Cornerstone Science Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">Janssen Cilag</orgName>
				</funder>
				<funder>
					<orgName type="full">Takeda</orgName>
				</funder>
				<funder>
					<orgName type="full">Eisai</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100003769</idno>
				</funder>
				<funder>
					<orgName type="full">Merck</orgName>
				</funder>
				<funder>
					<orgName type="full">Amgen</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100002429</idno>
				</funder>
				<funder ref="#_aEKZMr5">
					<orgName type="full">Galapagos</orgName>
				</funder>
				<funder>
					<orgName type="full">Trellus Health and Iterative Health</orgName>
				</funder>
				<funder>
					<orgName type="full">Pfizer</orgName>
				</funder>
				<funder>
					<orgName type="full">Abbott</orgName>
				</funder>
				<funder>
					<orgName type="full">Ferring</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100003122</idno>
				</funder>
				<funder>
					<orgName type="full">Satisfai Health</orgName>
				</funder>
				<funder>
					<orgName type="full">Prometheus Biosciences</orgName>
				</funder>
				<funder>
					<orgName type="full">Alimentiv (formerly Robarts)</orgName>
				</funder>
				<funder>
					<orgName type="full">Miyarisan</orgName>
				</funder>
				<funder>
					<orgName type="full">Kissei</orgName>
				</funder>
				<funder>
					<orgName type="full">EA Pharma</orgName>
				</funder>
				<funder ref="#_YSyfeeN">
					<orgName type="full">The Leona M. and Harry B. Helmsley Charitable Trust</orgName>
				</funder>
				<funder>
					<orgName type="full">Avalo</orgName>
				</funder>
				<funder>
					<orgName type="full">Iota Biosciences</orgName>
				</funder>
				<funder>
					<orgName type="full">Arena Pharmaceuticals</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">(FRO), Finland (FIN), France (FRA), Germany (DEU), Greece (GRC), Greenland (GRL), ), Indonesia (IDN), Iran (IRN), Ireland (IRL), Israel (ISR), Italy (ITA), Japan (JPN), Kazakhstan (KAZ), Kuwait (KWT), Lebanon (LBN), Lithuania (LTU), Macao (MAC), Malaysia (MYS), Mexico (MEX), Moldova (MDA), Netherlands (NLD), New Zealand (NZL), Norway (NOR), Oman (OMN), Panama (PAN), Philippines (PHL), Poland (POL), Portugal (PRT), Puerto Rico (PRI), Romania (ROU), Russia (RUS), San Marino (SMR), Saudi Arabia (SAU), Serbia (SRB), Singapore (SGP), Slovakia (SVK), South Africa (ZAF), South Korea (KOR), Spain (ESP), Sri Lanka (LKA), Sweden (SWE), Switzerland (CHE), Taiwan (TWN), Tanzania (TZA), Thailand (THA), Türkiye (TUR), United Kingdom (GBR), United States of America (USA) and Uruguay (URY). Regions with ISO 3166-2 codes are as follows: Catalonia (ES-CT), England (GB-ENG), Northern Ireland (GB-NIR), Scotland (GB-SCT) and Wales (GB-WLS). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&apos;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&apos;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/. © The Author(s) 2025</p>
				</availability>
				<date type="published" when="2025-04-30">30 April 2025</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Lindsay</forename><surname>Hracs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Joseph</forename><forename type="middle">W</forename><surname>Windsor</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Julia</forename><surname>Gorospe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Cummings</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stephanie</forename><surname>Coward</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Buie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Joshua</forename><surname>Quan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Quinn</forename><surname>Goddard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Léa</forename><surname>Caplan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ante</forename><surname>Markovinović</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tyler</forename><surname>Williamson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yvonne</forename><surname>Abbey</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Murdani</forename><surname>Abdullah</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">T</forename><surname>Abreu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vineet</forename><surname>Ahuja</surname></persName>
						</author>
						<author>
							<persName><roleName>Raja</roleName><forename type="first">Affendi</forename><surname>Raja</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mansour</forename><surname>Altuwaijri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Domingo</forename><surname>Balderramo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rupa</forename><surname>Banerjee</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><forename type="middle">I</forename><surname>Benchimol</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Charles</forename><forename type="middle">N</forename><surname>Bernstein</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eduard</forename><surname>Brunet-Mas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Johan</forename><surname>Burisch</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vui</forename><forename type="middle">Heng</forename><surname>Chong</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Iris</forename><surname>Dotan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Usha</forename><surname>Dutta</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sara</forename><surname>El Ouali</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Angela</forename><surname>Forbes</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anders</forename><surname>Forss</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><surname>Gearry</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Viet</forename><forename type="middle">Hang</forename><surname>Dao</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Juanda</forename><forename type="middle">Leo</forename><surname>Hartono</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ida</forename><surname>Hilmi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Phoebe</forename><surname>Hodges</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gareth-Rhys</forename><surname>Jones</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fabián</forename><surname>Juliao-Baños</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jamilya</forename><surname>Kaibullayeva</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Kelly</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Taku</forename><surname>Kobayashi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paulo</forename><forename type="middle">Gustavo</forename><surname>Kotze</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">L</forename><surname>Lakatos</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Charlie</forename><forename type="middle">W</forename><surname>Lees</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Julajak</forename><surname>Limsrivilai</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bobby</forename><surname>Lo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Edward</forename><forename type="middle">V</forename><surname>Loftus</surname><genName>Jr</genName></persName>
						</author>
						<author>
							<persName><forename type="first">Jonas</forename><forename type="middle">F</forename><surname>Ludvigsson</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Joyce</forename><forename type="middle">W Y</forename><surname>Mak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yinglei</forename><surname>Miao</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ka</forename><forename type="middle">Kei</forename><surname>Ng</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shinji</forename><surname>Okabayashi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ola</forename><surname>Olén</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Remo</forename><surname>Panaccione</surname></persName>
						</author>
						<author>
							<persName><roleName>Mukesh</roleName><forename type="first">Sharma</forename><surname>Paudel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Abel</forename><surname>Botelho Quaresma</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><forename type="middle">T</forename><surname>Rubin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marcellus</forename><surname>Simadibrata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yang</forename><surname>Sun</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hidekazu</forename><surname>Suzuki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Toro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dan</forename><surname>Turner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Beatriz</forename><surname>Iade</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shu</forename><forename type="middle">Chen</forename><surname>Wei</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jesus</forename><forename type="middle">K</forename><surname>Yamamoto-Furusho</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Suk-Kyun</forename><surname>Yang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Siew</forename><forename type="middle">C</forename><surname>Ng</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gilaad</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Australia (AUS) , Austria (</note>
								<orgName type="institution">AUS</orgName>
								<address>
									<country>Australia Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<note type="raw_affiliation">AUT) , Bahrain (BHR) , (BRA) , Brunei (</note>
								<orgName type="department">BHR</orgName>
								<orgName type="laboratory">BRA</orgName>
								<orgName type="institution">AUT)</orgName>
								<address>
									<settlement>Brunei</settlement>
									<country key="BH">Bahrain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">BRN) , Canada (CAN) , China (</note>
								<orgName type="institution">BRN)</orgName>
								<address>
									<country>Canada (CAN China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">CHN) , Colombia (</note>
								<orgName type="institution">CHN)</orgName>
								<address>
									<country key="CO">Colombia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">COL) , Croatia (</note>
								<orgName type="institution">COL)</orgName>
								<address>
									<country key="HR">Croatia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">HRV) , Cyprus (CYP) , Czechia (CZE</note>
								<orgName type="institution">HRV)</orgName>
								<address>
									<region>CYP</region>
									<country>Cyprus Czechia (CZE</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">) , Denmark (</note>
								<orgName type="institution">)</orgName>
								<address>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">DNK) , Estonia (</note>
								<orgName type="institution">DNK)</orgName>
								<address>
									<country key="EE">Estonia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<note type="raw_affiliation">EST) , Faroe Islands Guadeloupe and Martinique (GLP and MTQ) ,</note>
								<orgName type="department">Guadeloupe and Martinique (GLP and MTQ)</orgName>
								<orgName type="institution">EST)</orgName>
								<address>
									<country key="FO">Faroe Islands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<note type="raw_affiliation">Hong Kong (HKG) , Hungary (</note>
								<orgName type="institution">Hong Kong (HKG)</orgName>
								<address>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<note type="raw_affiliation">HUN) , Iceland (ISL</note>
								<orgName type="institution">HUN)</orgName>
								<address>
									<country>Iceland (ISL</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<note type="raw_affiliation">) , India (</note>
								<orgName type="institution">)</orgName>
								<address>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<note type="raw_affiliation">IND</note>
								<orgName type="institution">IND</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_wdyVsv3">Global evolution of inflammatory bowel disease across epidemiologic stages</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2025-04-30">30 April 2025</date>
						</imprint>
					</monogr>
					<idno type="MD5">2C8FB816F91E957D7C73B56A0AA202D9</idno>
					<idno type="DOI">10.1038/s41586-025-08940-0</idno>
					<note type="submission">Received: 8 January 2024 Accepted: 26 March 2025</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="595.22" lry="842.0"/>
		<surface n="22" ulx="0.0" uly="0.0" lrx="595.22" lry="842.0"/>
		<surface n="23" ulx="0.0" uly="0.0" lrx="595.22" lry="842.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_HqnFPWA"><p xml:id="_7napUcP"><s xml:id="_2TXSkNk">During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania <ref type="bibr" target="#b0">1</ref> .</s><s xml:id="_XemQckC">At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> .</s><s xml:id="_phk34X3">Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases.</s><s xml:id="_a9kz5Bb">A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced.</s><s xml:id="_agrhdnc">To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points.</s><s xml:id="_tmGmKZG">Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920-2024), we show spatiotemporal transitions across stages 1-3 and model stage 4 progression.</s><s xml:id="_vtT6GQT">Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.</s><s xml:id="_QddAyhX">IBD, consisting of Crohn's disease (CD) and ulcerative colitis (UC), was first recognized in the 1800s <ref type="bibr">5</ref> .</s><s xml:id="_8vcqrGy">In the early twentieth century, IBD was considered a rare disease among the descendants of Europeans who colonized North America and Oceania (hereafter referred to as early industrialized regions) <ref type="bibr" target="#b2">3</ref> .</s><s xml:id="_XZhNDYF">The changing epidemiology of IBD is characterized in terms of incidence (new diagnoses reported per 100,000 person-years) and prevalence (total affected individuals per 100,000 persons at a given time); for brevity, the units 'per 100,000' are omitted in the following text.</s><s xml:id="_DNZdevc">After the Second World War, the incidence of IBD in early industrialized regions increased rapidly <ref type="bibr" target="#b2">3</ref> .</s><s xml:id="_4W5sUA2">Although the reasons for this increase remain incompletely understood, evidence suggests environmental factors associated with Westernization of society-for example, increased smoking, Western diet and improved hygiene-may have substantially contributed by altering mucosal immune responses to the intestinal microbiome in genetically susceptible individuals <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> .</s></p><p xml:id="_UUgRu2C"><s xml:id="_VeJvXkg">During the latter half of the twentieth century, IBD was infrequently diagnosed in regions of Africa, Asia and Latin America that predominantly began industrialization after the Second World War (hereafter, newly industrialized regions) and low-income, developing areas (hereafter, emerging regions) <ref type="bibr" target="#b2">3</ref> .</s><s xml:id="_TQvAPYC">By the twenty-first century, the incidence stabilized in many early industrialized regions, except in children, in whom it continues to rise, whereas the prevalence of IBD continued to climb steadily across all age groups <ref type="bibr" target="#b3">4,</ref><ref type="bibr">8</ref> .</s><s xml:id="_5Rf7HE4">Although IBD cases in emerging regions remain sporadic, since 2000, newly industrialized regions have reported a sharp increase in the incidence of UC, followed by CD <ref type="bibr" target="#b0">1</ref> .</s><s xml:id="_f2KhzAQ">Today, IBD affects millions of people worldwide <ref type="bibr" target="#b3">4</ref> .</s></p><p xml:id="_TPsjhxK"><s xml:id="_MzusJ6X">The globalization of IBD has invalidated the historical notion that IBD is specific to the 'Western world' <ref type="bibr" target="#b0">1</ref> .</s><s xml:id="_7pWrRH6">Here, we advance the theory that IBD evolves temporally and spatially across four distinct epidemiologic stages.</s><s xml:id="_WJWCSy5">Stage 1 (emergence) is characterized by low incidence and prevalence; stage 2 (acceleration in incidence) involves rapidly rising incidence year-over-year, while the prevalence remains low; stage 3 (compounding prevalence) is marked by the slowing, stabilization or decrease in the incidence, with the prevalence continuing to accumulate due to decades of rising incidence outpacing mortality; and stage 4 (prevalence equilibrium) occurs when the prevalence plateaus due to mortality approximating incidence as the IBD population advances in age <ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_5w8RQmJ">By clearly defining these epidemiologic strata with specific benchmarks for transition across stages, regions can better prepare their healthcare systems to manage the stage-specific burden of IBD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vYHMBQP">Trends in incidence and prevalence of IBD</head><p xml:id="_7xt47F5"><s xml:id="_rDVb9S7">We identified real-world data of 522 population-based studies reporting the incidence (n = 463) and/or prevalence (n = 243) of CD and/or UC, encompassing 82 countries, nations or territories (henceforth referred to as regions) and spanning the years 1920-2024 (Supplementary Fig. <ref type="figure" target="#fig_0">1</ref> and Supplementary Tables <ref type="table">1</ref> and <ref type="table">2</ref>).</s><s xml:id="_ghvKPhC">Over the past century, the epidemiologic trends in the incidence (Fig. <ref type="figure" target="#fig_0">1a</ref>,<ref type="figure">b</ref>) and prevalence (Fig. <ref type="figure" target="#fig_0">1c</ref>,<ref type="figure">d</ref>) of IBD follow distinct geographical and temporal patterns.</s></p><p xml:id="_9FbE9Nc"><s xml:id="_BYYKM34">UC was first recognized in the nineteenth century, while Crohn, Ginzburg and Oppenheimer's seminal 1932 paper on regional ileitis (later, CD) solidified CD as a distinct condition <ref type="bibr">5,</ref><ref type="bibr" target="#b8">9</ref> .</s><s xml:id="_VgskmWZ">Consequently, data on the incidence of IBD during the early decades of the twentieth century are sparse, and prevalence data are non-existent (Fig. <ref type="figure" target="#fig_0">1</ref> and Supplementary Fig. <ref type="figure" target="#fig_6">2</ref>).</s><s xml:id="_4XfSkqG">Today, with over a century of epidemiologic data, we can analyse distributions by region and decade.</s><s xml:id="_ZaKEhee">We calculated coalescing ranges (CR) for incidence (CR-I) and prevalence (CR-P), as defined by the 25th-75th percentiles within these strata.</s><s xml:id="_t2Cdhtk">By the 1940s, the diagnosis of IBD was established in early industrialized regions (Fig. <ref type="figure" target="#fig_0">1a</ref>,<ref type="figure">b</ref>).</s><s xml:id="_kTHmnsX">For example, in the 1940s, the CR-I for CD and UC in the United States was 1.15-2.30</s><s xml:id="_wcqwcWj">and 1.02-2.41,</s><s xml:id="_yqZGdyW">respectively, while in the 1950s, Europe showed a rising IBD incidence, with UC more commonly diagnosed than CD, such as Sweden's CR-I of 1.88-7.50</s><s xml:id="_fY8Ny8Z">for UC and 0.97-2.18</s><s xml:id="_cqQhA49">for CD (Fig. <ref type="figure" target="#fig_0">1a</ref>,<ref type="figure">b</ref> and Supplementary Figs.</s><s xml:id="_tDn7Ym8"><ref type="figure" target="#fig_2">3a</ref> and <ref type="figure" target="#fig_3">4a</ref>).</s></p><p xml:id="_HBJsnYJ"><s xml:id="_PJSZZ35">Subsequently, early industrialized regions in North America, Europe and Oceania experienced rapidly rising incidence, which stabilized in many regions around the turn of the twenty-first century (Fig. <ref type="figure" target="#fig_0">1a</ref>,<ref type="figure">b</ref>).</s><s xml:id="_SscdfJA">Longitudinal data from Cardiff, Wales (1931-2008) demonstrated a steady increase in CD incidence, with rates nearly doubling each decade from 1.17 (1946-1955) to 7.09 (1976-1985), before levelling off at 5.88 (1986-1995) and 6.64 (1996-2005)  <ref type="bibr" target="#b9">10</ref> (Supplementary Fig. <ref type="figure" target="#fig_4">5a</ref>).</s></p><p xml:id="_vEmRqxX"><s xml:id="_qk2gBDk">The highest incidence of IBD, particularly UC, has been reported in Scandinavia (Fig. <ref type="figure" target="#fig_0">1a</ref>,<ref type="figure">b</ref>).</s><s xml:id="_cRKZAFD">In Denmark, incidence steadily increased from the 1970s (CR-I: 2.05-3.55 for CD; 6.50-9.12</s><s xml:id="_JvEPr4V">for UC) to 1990s (CR-I: 7.30-10.68</s><s xml:id="_MhmjUEK">for CD; 13.18-20.99</s><s xml:id="_RuT9sCu">for UC) and to 2010s (CR-I: 12.62-15.84</s><s xml:id="_JpcwTm9">for CD; 22.21-30.64</s><s xml:id="_zQ8HaK7">for UC) (Fig. <ref type="figure" target="#fig_0">1a</ref>,b and Supplementary Fig. <ref type="figure">6a</ref>).</s><s xml:id="_KkbcRS3">The highest ever reported UC incidence was 73.7 in the Faroe Islands in 2011 (ref.</s><s xml:id="_jme3gYn">11) (Fig. <ref type="figure" target="#fig_0">1a</ref>,b and Supplementary Fig. <ref type="figure">7a</ref>).</s><s xml:id="_rtBpUJ7">Only a small number of early industrialized regions report population-based incidence exceeding 40 per 100,000 for either UC or CD separately (Extended Data Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_mJTa9fB">Thus, 40 per 100,000 serves as a ceiling threshold for the incidence of CD or UC.</s><s xml:id="_5AHB9Dm">Regions with methodologically reliable data that exceed this threshold should be prioritized for further study to identify environmental determinants of IBD.</s></p><p xml:id="_hGgXS2t"><s xml:id="_cMj3QhK">After decades of rising incidence in early industrialized regions, the prevalence of IBD has steadily climbed (Fig. <ref type="figure" target="#fig_0">1c</ref>,<ref type="figure">d</ref>).</s><s xml:id="_U8VGutq">In Olmsted County, the prevalence of IBD increased from 0.12% in 1965 to 0.35% in 1991, 0.56% in 2011 and 0.63% in 2019 (Supplementary Fig. <ref type="figure" target="#fig_2">3b</ref>).</s><s xml:id="_duyASmF">A separate US study estimated the national prevalence to be 0.72% in 2018 <ref type="bibr" target="#b11">12</ref> .</s><s xml:id="_xXa5U5t">In Lothian, Scotland, IBD prevalence increased from 0.57% to 0.78% between 2008 and 2018 (ref.</s><s xml:id="_bWsmrGb">13) (Supplementary Fig. <ref type="figure">8b</ref>), with forecasts from Canada and Scotland predicting that 1% of the population will be living with IBD by 2030 <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> .</s></p><p xml:id="_ZK8CKAs"><s xml:id="_verR5rG">During the twentieth century, epidemiologic data from newly industrialized and emerging regions in Africa, Asia and Latin America were sparse, with any available data reporting incidence and prevalence far lower than those in early industrialized regions (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_43acy5N">By the turn of the twenty-first century, epidemiologic data began to indicate that newly industrialized regions were entering a stage of rapidly increasing incidence.</s><s xml:id="_WhSzz6S">This increase in reported incidence can be attributed to both improved identification of cases through advanced diagnostic capabilities and a true increase in incidence driven by environmental determinants <ref type="bibr">5,</ref><ref type="bibr" target="#b6">7</ref> .</s></p><p xml:id="_yUHGTgj"><s xml:id="_q9nySC8">Japan provides some of the earliest data from a newly industrialized region, spanning 1955 to 2000 (Fig. <ref type="figure" target="#fig_0">1a</ref>,b and Supplementary Fig. <ref type="figure">9</ref>).</s><s xml:id="_WRap2Pd">The incidence of IBD in Japan before the 1970s was less than 0.25, increasing to over 0.4 by 1980.</s><s xml:id="_swJrEwA">By 2000, the incidence had increased tenfold reaching 4.77 and 1.27 for UC and CD, respectively (Supplementary Fig. <ref type="figure">9a</ref>).</s><s xml:id="_s24CRSj">South Korea showed similar patterns, with low incidence in the 1980s (CR-I: 0-0.03 for CD; 0.21-0.33 for UC) increasing steadily into the 2010s (CR-I: 2.20-3.20 for CD; 4.11-6.27</s><s xml:id="_cc3TDUc">for UC) (Fig. <ref type="figure" target="#fig_0">1a</ref>,<ref type="figure">b</ref> and Supplementary Fig. <ref type="figure" target="#fig_0">10a</ref>).</s><s xml:id="_8uGNWgq">Regions with slower economic development experienced a delayed onset of rapidly rising incidence, as seen in China and Malaysia, where incidence substantially increased after 2000 (Supplementary Figs.</s><s xml:id="_HgRebjZ"><ref type="figure" target="#fig_0">11a</ref> and <ref type="figure" target="#fig_6">12a</ref>).</s></p><p xml:id="_eCaP7wv"><s xml:id="_QG8qGMb">Brazil demonstrates a clear case of rising incidence in Latin America, starting with low rates in the 1980s (CR-I: 0.08-0.40</s><s xml:id="_cGxRpzP">for CD; 0-0.46 for UC), and increasing in the 2000s (CR-I: 0.34-0.98 for CD; 0.53-1.04</s><s xml:id="_keBtAhH">for UC) and 2010s (CR-I: 1.21-3.22</s><s xml:id="_CSZTKg7">for CD; 2.42-5.66 for UC) (Fig. <ref type="figure" target="#fig_0">1a</ref>,b and Supplementary Fig. <ref type="figure" target="#fig_2">13a</ref>).</s><s xml:id="_zjyTrXJ">Heterogeneity within Brazil highlights higher IBD incidence in more-urbanized, developed areas; for example, the prevalence in the more densely populated and economically advanced São Paulo (182.81 in 2020) was three times that of Piauí (59.94 in 2020) <ref type="bibr" target="#b15">16</ref> .</s></p><p xml:id="_rTStkEz"><s xml:id="_GKhYftz">The highest prevalence of IBD in newly industrialized regions was observed in areas where incidence increased earlier.</s><s xml:id="_JRG4uBp">Japan's prevalence increased from 0.067% in 2000 to 0.165% in 2016 (Supplementary Fig. <ref type="figure">9b</ref>).</s><s xml:id="_MR7gFxx">Brazil showed a similar trend, with prevalence rising from 0.014% in 2000 to 0.1% by 2020 (Supplementary Fig. <ref type="figure" target="#fig_2">13b</ref>).</s><s xml:id="_G3vVGzW">By contrast, regions in which the incidence surged after 2000 report much lower prevalence.</s><s xml:id="_ayWRTmb">For example, Colombia's prevalence reached 0.067% in 2017 (Supplementary Fig. <ref type="figure" target="#fig_3">14b</ref>), matching Japan's 2000 level.</s><s xml:id="_4GxyEbE">Similarly, China (Supplementary Fig. <ref type="figure" target="#fig_0">11b</ref>), Malaysia (Supplementary Fig. <ref type="figure" target="#fig_6">12b</ref>) and Taiwan (Supplementary Fig. <ref type="figure" target="#fig_4">15b</ref>) all had an IBD prevalence below 0.03% in the most recent year of data (China, 2016; Malaysia, 2018; Taiwan, 2023).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NEWmhKp">The first three epidemiologic stages of IBD</head><p xml:id="_UqR7nnG"><s xml:id="_j7Xvd6r">The observed differences in IBD incidence and prevalence across various geographical areas over the past century suggest that epidemiologic patterns shift through time.</s><s xml:id="_bbFrh5s">To further explore these trends and characterize the epidemiology of IBD independently of geography and time, we developed a machine-learning classifier to determine the epidemiologic stage of global regions.</s><s xml:id="_dEYKTzC">This methodology not only automates the classification of stages across a large, heterogenous dataset but also establishes benchmarks for incidence and prevalence that can be applied to new data as they become available.</s></p><p xml:id="_7JSqpKP"><s xml:id="_wxU6CyT">Derived from the systematic review, the observed incidence and prevalence data, along with their change over time (Supplementary Fig. <ref type="figure" target="#fig_0">16</ref>), informed an iterative labelling process that resulted in a training dataset with a subset of regions labelled as epidemiologic stage 1, Article 2 or 3. We began with the assumption that many early industrialized regions are currently in stage 3. From there, we visually inspected historical trends in these regions to define preliminary stage assignments on the basis of observable changes in the epidemiology of stages 1 and 2. These observed trends were visually compared to trends in emerging and newly industrialized regions suspected to be in stage 1 or 2 to lowest (bottom) most recent median prevalence value available.</s><s xml:id="_8Cjvrm5">Colour saturation represents median incidence/prevalence, calculated from all studies within a given region for that decade.</s><s xml:id="_weFUEUX">CR values (25th to 75th percentiles) of incidence/prevalence for the corresponding region-decade pairing are provided in Supplementary Fig. <ref type="figure" target="#fig_6">2</ref>. All data are available at Figshare (<ref type="url" target="https://doi.org/10.6084/m9.figshare.24952557">https://doi.org/10.6084/  m9.figshare.24952557</ref>).</s><s xml:id="_5BRcXYV">An interactive map depicting year-over-year changes in incidence and prevalence is available online (<ref type="url" target="https://kaplan-gi.shinyapps.io/GIVES21/">https://kaplan-gi.shinyapps.io/  GIVES21/</ref>).</s><s xml:id="_naBZ5Jt">Regions are labelled with their International Organization for Standardization (ISO) 3166-1 alpha-3 codes: Algeria (DZA), Argentina (ARG), to corroborate classifications.</s><s xml:id="_nDEb54P">This method enabled us to effectively compare current low-incidence regions with historical periods of lower incidence in current high-incidence regions, establishing equivalencies across varying times and geographies.</s></p><p xml:id="_ACSZUDf"><s xml:id="_FaDNDPc">A k-nearest neighbours (k-NN) <ref type="bibr" target="#b16">17</ref> model supported the manual labelling process, facilitating an iterative refinement of classifications until stage labels for a subset of data were agreed upon by three independent reviewers.</s><s xml:id="_vJ2q8KP">The labelled dataset was used as the training input for a random-forest classifier <ref type="bibr" target="#b17">18</ref> , which used the magnitude of incidence and prevalence, along with the rates of change, to inform the model and define the three epidemiologic stages (Extended Data Fig. <ref type="figure" target="#fig_6">2</ref>).</s><s xml:id="_54erh8Y">After classification using a supervised random-forest model, benchmarked CR-I and CR-P values corresponding to stages 1-3 were calculated (Fig. <ref type="figure" target="#fig_6">2</ref>).</s><s xml:id="_BjQgWN2">Although the number of epidemiologic stages was predefined, the supervised machine-learning classifier accurately classified unseen validation data into the three stages with a high accuracy of 95.15% (95% confidence interval (CI) = 92.60-97.01).</s><s xml:id="_q2t5NhM">Classification errors on validation data mainly occurred in regions with datapoints between the CRs, which probably represent regions in transition toward the next epidemiologic stage.</s></p><p xml:id="_SrNaXPM"><s xml:id="_Mn3cs5h">Negative binomial regression models with post hoc comparisons of estimated marginal means with Tukey adjustment revealed significant differences between all stages for the incidence and prevalence of CD and UC (all values, P &lt; 0.001).</s><s xml:id="_ThwxuG9">The clear distinctions across stages define the CRs for the incidence and prevalence of IBD-stage 1: CR-I = 0.1-1.2,</s><s xml:id="_b7XGbgt">CR-P = 1.2-10.5;</s><s xml:id="_7Ur85JM">stage 2: CR-I = 3.3-10.6,</s><s xml:id="_SzNaUFT">CR-P = 31.2-100.5;</s><s xml:id="_ugjbqbW">stage 3: CR-I = 18.1-34.1,</s><s xml:id="_bhMWMmT">CR-P = 362.9-660.1 (Fig. <ref type="figure" target="#fig_6">2</ref>).</s><s xml:id="_9938wsp">Values that fall between CRs indicate regions transitioning between stages.</s><s xml:id="_RyNjC6E">For example, Taiwan was classified as stage 1 in 2010-2019, showing increases in incidence from 1.32 and prevalence from 11.24 in 2010 to an incidence of 2.51 and a prevalence of 21.16 in 2019.</s><s xml:id="_JgZjmNN">These rising trends suggest that Taiwan was transitioning towards stage 2; with newly available data, the model subsequently assigned a stage 2 classification in the 2020s based on prevalence of 29.2 in 2023 (Supplementary Fig. <ref type="figure" target="#fig_4">15b</ref>).</s><s xml:id="_3vymbvN">These ranges may help to define the burden of IBD on healthcare systems by providing estimated numbers of incident and prevalent IBD cases year over year For the box plots, the centre line shows the median, the lower hinge shows the 25th percentile (that is, first quartile) and the upper hinge shows the 75th percentile (that is, third quartile).</s><s xml:id="_wGPvacx">The 25th and 75th percentiles are labelled and correspond to the CRs.</s><s xml:id="_bd2NJXr">Statistical analysis was performed using negative binomial regression with post hoc comparisons of estimated marginal means with Tukey adjustment for multiple comparisons, showing significant differences between all stages for the incidence and prevalence of CD and UC (P &lt; 0.001 for all comparisons).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xRBztyg">Article</head><p xml:id="_tWCt6aV"><s xml:id="_yut9psu">and linking the estimated rates to their respective costs and resource needs <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b18">19</ref> .</s><s xml:id="_6bv5PZt">An overall increase in incidence rates was observed over time across stages 1, 2 and 3, with several regions transitioning to stage 3 after 1990 (Extended Data Fig. <ref type="figure" target="#fig_6">2</ref>).</s><s xml:id="_debJx45">Prevalence remains consistently low in regions classified as stage 1.</s><s xml:id="_YUM746v">Prevalence noticeably increases in stage 2 and then rises rapidly in stage 3 (Extended Data Fig. <ref type="figure" target="#fig_6">2</ref>).</s><s xml:id="_cdGWQrc">Our findings demonstrate regional transitions across stages and highlight the increasing number of regions included in population-based studies over time (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s xml:id="_KuE3ZEn">For example, data spanning a century from the United States display a transition from stage 1 to stage 2 in the 1950s, followed by a shift to stage 3 in the 1970s.</s><s xml:id="_Y5E4BKW">Today, most early industrialized regions in Europe, North America and Oceania are classified as stage 3, while many newly industrialized regions in Latin America, East Asia and the Middle East are in stage 2 (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s xml:id="_ZRjgDB6">Data from emerging regions in stage 1 (such as many regions in Africa) remain limited, as data scarcity is a typical characteristic of this stage.</s></p><p xml:id="_zUNsE9w"><s xml:id="_3xndchE">The underlying drivers of transition across stages remain unclear.</s><s xml:id="_maSFe5y">The shift from stage 1 to 2 can be partially attributed to the unmasking of incidence.</s><s xml:id="_UNJSH45">As IBD begins to emerge in a region, the local medical infrastructure (such as access to colonoscopy) must be sufficient to diagnose CD.</s><s xml:id="_vNgjxzE">In low-income regions where access to colonoscopy is more limited than sigmoidoscopy, cases of CD may be misdiagnosed as UC or missed entirely.</s><s xml:id="_mr2bX4u">We observed a significant difference (P &lt; 0.001) in the UC:CD ratio across the three epidemiologic stages: a median ratio of 3.24:1 in stage 1, decreasing to 1.87:1 in stage 2 and further to 1.54:1 in stage 3 (Supplementary Fig. <ref type="figure" target="#fig_0">17</ref>).</s></p><p xml:id="_9ABcsh3"><s xml:id="_TrqPAz6">Beyond the unmasking of incidence, environmental factors have also contributed to a true increase in incidence.</s><s xml:id="_brH8FfZ">Industrialization, urbanization and Westernization have been linked to increasing incidence of IBD <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr">[5]</ref> .</s><s xml:id="_p4dTxv7">To quantify societal changes over time, we examined five time-and region-specific indicators: the Augmented Human Development Index (AHDI) <ref type="bibr" target="#b19">20</ref> , obesity <ref type="bibr" target="#b20">21</ref> , percentage urbanization <ref type="bibr" target="#b21">22</ref> , the Universal Health Coverage Service Index <ref type="bibr" target="#b22">23</ref> and the Western Diet Index (WDI) <ref type="bibr" target="#b23">24</ref> (Methods).</s><s xml:id="_yxZmZwU">Each of these societal indicators showed a significant difference when analysed by stage (Extended Data Fig. <ref type="figure" target="#fig_2">3</ref>); for example, on a 0-1 scale, the median AHDI increased from 0.39 in stage 1 to 0.53 in stage 2 and to 0.70 in stage 3 (P &lt; 0.001 between epidemiologic stages).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_B5xGX6k">Mathematically modelling the transition to stage 4</head><p xml:id="_vkwhANc"><s xml:id="_zVnyYj5">Partial differential equations (PDEs) were developed to model timedependent prevalence <ref type="bibr" target="#b24">25</ref> for three stage 3 regions: Canada, Denmark and Scotland.</s><s xml:id="_tu3wwPf">Prevalence was modelled out to 2043, the last common year of projected population data available 26-28 (Fig. <ref type="figure" target="#fig_3">4a</ref>).</s><s xml:id="_QTsNpH6">On the basis of the assumption of stable incidence over time, calculated as the mean incidence for each age group over the most recent 8-year period, the models indicate a rising prevalence in each region: Canada (0.65% in 2014 to 0.83% in 2025 to 0.96% in 2035 to 1.05% in 2043); Denmark (0.86% in 2014 to 1.19% in 2025 to 1.44% in 2035 to 1.59% in 2043); and Scotland (0.74% in 2014 to 1.04% in 2025 to 1.32% in 2035 to 1.51% in 2043) (Fig. <ref type="figure" target="#fig_3">4a</ref>).</s><s xml:id="_eNq6W9a">Time-dependent prevalence stratified by IBD type shows a similar distribution of CD and UC prevalence in Canada over the next 20 years, while UC is projected to be more prevalent than CD in Scotland and Denmark (Supplementary Fig. <ref type="figure" target="#fig_0">18a</ref>,<ref type="figure">b</ref>).</s></p><p xml:id="_cVxQj2f"><s xml:id="_exBxky6">Modelled prevalence continues to climb for each region; however, the rate of prevalence growth decreases, signalling a transition towards stage 4.</s><s xml:id="_XBAffhW">This transition occurs as mortality begins to approximate incidence, leading to a slowing of prevalence growth-a state driven by an ageing IBD population.</s><s xml:id="_n2YS8kW">For example, in Canada (observed data, 2007-2014), we observe a greater growth in prevalence among older adults compared with in the paediatric and young-adult age groups (Supplementary Fig. <ref type="figure" target="#fig_0">19a</ref>); similar trends are seen in Denmark (observed data, 2010-2017) and Scotland (observed data, 2010-2017) (Supplementary Fig. <ref type="figure" target="#fig_0">19b</ref>,<ref type="figure">c</ref>).</s><s xml:id="_7EKCsBw">In each region, PDE-modelled prevalence indicates that the prevalence among older adults and older people with IBD will steadily increase across 2023-2043 (Supplementary Fig. <ref type="figure" target="#fig_0">19a-c</ref>).</s></p><p xml:id="_hZXxQ4M"><s xml:id="_pZV76c8">The prevalence growth rate (that is, slope) decreases in each analysed region, as calculated using central difference approximations <ref type="bibr" target="#b28">29</ref> (Fig. <ref type="figure" target="#fig_3">4b</ref>).</s><s xml:id="_FcP3EEF">In Canada, the slope decreases from 0.018% per year in 2015 to 0.010% per year in 2042.</s><s xml:id="_XdJQEyZ">In Denmark and Scotland, the slope decreases from 0.033% per year in 2018 to 0.018% and 0.022% per year in 2042, respectively.</s><s xml:id="_Zdr6JQQ">When examining a 20-year period of overlapping data (2022-2042), all three regions exhibit similar reductions in prevalence growth rates (P = 0.947).</s><s xml:id="_KMR8PnA">A slowing of prevalence growth rates was also observed in central difference approximations for both CD and UC (Supplementary Fig. <ref type="figure" target="#fig_0">18c</ref>,<ref type="figure">d</ref>).</s></p><p xml:id="_jBB2PSY"><s xml:id="_xWwQPxb">In addition to modelling prevalence with stable incidence rates, we modelled four additional incidence rate scenarios: 2% and 1% decreases in incidence per year, and 1% and 2% increases in incidence per year.</s><s xml:id="_k6dpBtp">These incidence scenarios were modelled for Canada (Fig. <ref type="figure" target="#fig_4">5a</ref>), Denmark (Fig. <ref type="figure" target="#fig_4">5b</ref>) and Scotland (Fig. <ref type="figure" target="#fig_4">5c</ref>).</s><s xml:id="_xg82pjy">The no-change scenario corresponds to model predictions based on stable average incidence for each region (Fig. <ref type="figure" target="#fig_3">4a</ref>).</s><s xml:id="_dmrEPtY">In 2043, the modelled prevalence across incidence scenarios (-2% to 2%) ranges between 0.97% and 1.16% for Canada, 1.45% and 1.76% for Denmark, and 1.36% and 1.69% for Scotland.</s></p><p xml:id="_3ug89Jx"><s xml:id="_dRPqQ5Z">We propose that stage 4-prevalence equilibrium-occurs when the change in prevalence slope reduces to an average of 0% (±0.01%) over a 5-year period.</s><s xml:id="_hYAHXC2">Under the model assumption of stable yearly incidence, prevalence slope changes near 2040 are approaching zero; however, by 2042, only Canada (among analysed regions) reaches this threshold (Extended Data Table <ref type="table">1</ref>).</s><s xml:id="_CtpjEn7">Thus, if incidence remains stable, the models suggest that it will take decades for the examined stage 3 regions to reach prevalence equilibrium.</s><s xml:id="_qjTJfxN">If incidence is decreased by 2% per year through preventative medicine and policy interventions targeting modifiable behavioural and environmental exposures, our models suggest that prevalence equilibrium may be achievable in the 2040s for all three regions <ref type="bibr" target="#b29">30</ref> (Fig. <ref type="figure" target="#fig_4">5d</ref>-f and Extended Data Table <ref type="table">2</ref>).</s><s xml:id="_u5bX83a">Prevalence equilibrium is a desired state in the evolution of IBD for healthcare administrators and policymakers, as it would allow for appropriate allocation of resources to ensure timely, high-quality healthcare for those affected with IBD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tG28JnW">Discussion</head><p xml:id="_F9Vj3WH"><s xml:id="_TSjwSX8">IBD serves as a case study on the evolution of chronic inflammatory diseases that have predominantly manifested in the last two centuries following the industrial revolution <ref type="bibr">5</ref> .</s><s xml:id="_bA4Zsc7">For centuries, the occurrence of IBD was confined to sporadic incident cases with persistently low prevalence (stage 1: emergence) <ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_szyB4XN">Economic advancement, industrialization, urbanization, improved healthcare access and delivery, and shifting environmental exposures trigger a rapid increase in incidence, whereas prevalence levels remain low (stage 2: acceleration in incidence) <ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_Phem96Q">IBD is typically diagnosed in young adults and, as mortality remains low, prevalence steadily climbs (stage 3: compounding prevalence) <ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_eVsedcM">During stage 3, incidence rates tend to show less growth, stabilize or even decline; this, combined with an aging IBD population, is proposed to slow prevalence growth, and eventually plateau (stage 4: prevalence equilibrium) <ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_QF3ZXE3">Understanding IBD epidemiology prepares healthcare systems for the increasing burden of IBD as regions transition through these stages <ref type="bibr" target="#b30">31</ref> .</s></p><p xml:id="_A5MYy4S"><s xml:id="_wfgndwB">Several low-income regions in Africa, Asia and Latin America are likely in stage 1.</s><s xml:id="_JdphHUa">The exact drivers and timing of transition to stage 2 are unclear.</s><s xml:id="_xA3gFWW">However, in the absence of robust epidemiologic data, societal-level indicators such as the AHDI may provide insights into an impending increase in IBD cases as economies develop, healthcare infrastructure improves and lifestyles shift towards environmental factors that trigger IBD.</s><s xml:id="_X7DZmM3">As these regions transition to stage 2, raising awareness of IBD, differentiating from infectious diseases, and enhancing training and resources, including access to colonoscopy, are crucial <ref type="bibr" target="#b31">32</ref> .</s><s xml:id="_v5bcBHS">Population-based studies in regions with sparse data, particularly Africa, are essential.</s><s xml:id="_zwB8vB4">Moreover, studying regions as they progress into stage 2 offers opportunities to investigate genetic, environmental and microbial determinants of IBD <ref type="bibr" target="#b32">33</ref> .</s></p><p xml:id="_cWH3gq5"><s xml:id="_B9KePgt">Many newly industrialized regions in Asia and Latin America are currently in stage 2, with robust population-based data indicating rising incidence throughout the past two decades.</s><s xml:id="_38GkmCr">Japan and South Korea, which underwent rapid industrialization in the latter half of the twentieth century, have reported prevalence exceeding 0.1%, placing them on the brink of transitioning towards stage 3 <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35</ref> .</s><s xml:id="_EHgBNpJ">By contrast, regions like China and Malaysia, which industrialized later, entered stage 2 more recently, and report fivefold lower prevalence <ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37</ref> .</s><s xml:id="_TYTx3Z4">Even if newly industrialized regions never reach the incidence and prevalence levels of IBD seen in Europe, achieving a prevalence of 0.1% over the next few decades will still impose a substantial burden on societies with large populations like India and China.</s><s xml:id="_nRMFeEF">Moreover, the age distribution of IBD cases in these regions is likely to be skewed towards the young <ref type="bibr" target="#b37">38</ref> , exacerbating the economic burden for working-age adults with IBD or caregivers of children with IBD.</s><s xml:id="_3G8mr29">As managing IBD is expensive, equitable access to treatments is essential to avoid the indirect burden of a chronic illness in a young population, such as loss of work productivity <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b38">39</ref> .</s></p><p xml:id="_8MGeWp5"><s xml:id="_dhATsyQ">Many early industrialized regions are in stage 3. Variations in IBD-susceptibility genes and environmental exposures influence the magnitude and change of incidence over time <ref type="bibr" target="#b39">40</ref> .</s><s xml:id="_jBFTxqd">Methodological differences in surveillance systems may also contribute to heterogeneity, potentially leading to outliers in epidemiologic data <ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b41">42</ref> .</s><s xml:id="_vuy2Zkt">Stage 3 regions face the rising burden of IBD, with increasing numbers of individuals living with IBD and a growing proportion of older people.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_W4PURTZ">Article</head><p xml:id="_VrzNfGJ"><s xml:id="_Athd9e2">These regions must balance the demands of new diagnoses in young individuals with the intricacies of caring for an ageing IBD population.</s><s xml:id="_9b59KPY">The challenges are particularly pronounced in adult gastroenterology clinics, as managing IBD with immunosuppressive therapies and/ or intestinal resections becomes more complex in older people with age-related comorbidities such as diabetes, cancer or dementia <ref type="bibr" target="#b42">43</ref> .</s><s xml:id="_quJjxcS">Proactive healthcare planning is essential, as multidisciplinary care teams will be needed to manage ageing IBD populations <ref type="bibr" target="#b43">44</ref> .</s></p><p xml:id="_QtReQq4"><s xml:id="_sZwXyRe">Prevalence will continue to steadily climb while mortality is low 2 .</s><s xml:id="_9WWHuFt">However, the shifting demographics of an ageing IBD population over the next few decades is projected to slow the rate of prevalence growth: although the prevalence will still increase, it will do so at a slower pace.</s><s xml:id="_pmy58re">Assuming a stable incidence, the prevalence is estimated to range between 1.02% and 1.59% in the 2040s in Canada, Denmark and Scotland, and between 1.10% and 1.76% if the incidence increases by 2% per year.</s><s xml:id="_2NyTP6Z">Future epidemiologic studies in stage 3 regions that monitor the slowing of prevalence growth are essential for determining the timing of the transition to stage 4. Our models underscore that interventions aimed at reducing IBD incidence have the potential to stabilize and possibly decrease IBD prevalence.</s></p><p xml:id="_8DNP3vT"><s xml:id="_hKMkP9M">Prevention of some IBD cases is an ambitious yet potentially achievable goal <ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b44">45</ref> .</s><s xml:id="_GMzgjps">Pre-disease cohorts have linked biological markers (such as genes, serology, microorganisms) to future IBD development, indicating the potential to identify those at moderate risk who might benefit from targeted interventions, such as modifying their microbiome <ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref> .</s><s xml:id="_tt85WuJ">For those at higher risk, pharmaceutical interventions could be explored to delay IBD onset, similar to strategies used in type 1 diabetes with teplizumab <ref type="bibr" target="#b48">49</ref> and rheumatoid arthritis with abatacept <ref type="bibr" target="#b49">50</ref> .</s><s xml:id="_9jaSZtt">Observational research also indicates that lifestyle and dietary changes may reduce CD and UC incidence <ref type="bibr" target="#b29">30</ref> .</s><s xml:id="_6kmUTJG">Thus, prioritizing research on preventative strategies to reduce the risk of IBD is crucial.</s></p><p xml:id="_zvHmnD4"><s xml:id="_TZ4UJxk">This study represents the most comprehensive analysis of population-based data on IBD incidence and prevalence, but several limitations must be considered (see the 'Strengths and limitations' section in the Methods).</s><s xml:id="_tpt2FKe">The quality of data sources varied, particularly for historical data from the twentieth century and data from regions without robust healthcare surveillance systems.</s><s xml:id="_WRZFq3S">While our machine-learning classifier demonstrated high accuracy (&gt;95%), classification errors were more common in regions with limited data and in those transitioning between stages.</s><s xml:id="_Smj9Rwr">Investigating distinct transition phases between predefined stages or further subdividing these stages may become feasible as more longitudinal data from diverse regions become available.</s><s xml:id="_ag55ZXu">Moreover, the PDE model did not account for differential mortality between IBD and non-IBD populations, potentially overestimating future prevalence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YZE4xbR">Conclusion</head><p xml:id="_FNMK2hH"><s xml:id="_AT3EtDc">Incidence and prevalence data spanning the past century were analysed to explore epidemiologic trends in the evolution of IBD across the world.</s><s xml:id="_Q6wE3fJ">Machine-learning algorithms were applied to the data to create a classification system across three epidemiologic stages: stage 1 (emergence), low incidence and prevalence; stage 2 (acceleration in incidence), rapidly increasing incidence and low prevalence; and stage 3 (compounding prevalence), reduced incidence growth while prevalence rapidly increases.</s><s xml:id="_g9sayRN">Our classification system was used to define benchmarks for transition across these stages for regions worldwide.</s><s xml:id="_RQJFzkM">Modelling population demographics enabled us to predict prevalence over the next two decades, while also demonstrating the plateauing of prevalence that characterizes stage 4 (prevalence equilibrium).</s><s xml:id="_Eh3SczX">These data can be used by healthcare systems and society to address the rising global burden of IBD.</s><s xml:id="_rFMa359">Furthermore, the testable predictions made by the epidemiologic transition theory that we advance here should serve as a model for future researchers investigating analogous diseases with global, longitudinal epidemiologic data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PxSYUGg">Online content</head><p xml:id="_kZsDHwK"><s xml:id="_6csCwg2">Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <ref type="url" target="https://doi.org/10.1038/s41586-025-08940-0">https://doi.org/10.1038/s41586-025-08940-0</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gTNcx3C">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ex2EUUW">Systematic review</head><p xml:id="_TTeNTSh"><s xml:id="_KvTaUuh">We conducted a systematic review of population-based studies to investigate changes in incidence and prevalence of CD and UC across global regions over time.</s><s xml:id="_bxujAkW">The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement <ref type="bibr" target="#b59">51</ref> .</s></p><p xml:id="_dWp65Ab"><s xml:id="_67ArSNn">Search strategy.</s><s xml:id="_K6WYDcE">We reassessed population-based studies reporting the incidence and prevalence of IBD from our team's two previous systematic reviews <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref> , covering the period before 2017.</s><s xml:id="_BJbvBwn">We updated the previous systematic reviews by performing a search of Embase, MEDLINE, PubMed and Web of Science for the period covering 1 January 2017 to 8 May 2024 with no language restrictions (the search strategy is shown in Supplementary Table <ref type="table">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_K2Dr6h4">Study selection.</head><p xml:id="_DEUf2sP"><s xml:id="_ESgtdwF">All studies underwent independent title and abstract screening by at least two reviewers.</s><s xml:id="_vwrz7qD">The reference lists were also inspected for additional citations.</s><s xml:id="_bsTzDKJ">We included population-based studies published in article form at any time or abstracts from 2020 or later, which reported the incidence and/or prevalence of CD and/or UC separately or provided sufficient information to calculate the corresponding incidence or prevalence.</s><s xml:id="_6mpWchz">Population-based studies were defined as studies deriving incidence and/or prevalence for the entire population of a specified geographical region or a representative sample.</s><s xml:id="_RzxFsXs">Exclusion criteria were as follows: no defined geographical region, less than 1 year of data, study population limited to paediatric cases only, self-reported cases identified by survey, reviews and clinical trials.</s><s xml:id="_3RW6an4">Studies published in languages other than English were translated using Google Translate 52 .</s><s xml:id="_c8jpWbs">All included articles were re-evaluated by authors with local expertise and local language proficiency (see the 'Data verification' section below).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GQe6gAB">Data extraction.</head><p xml:id="_5Gf3tDG"><s xml:id="_tjETtQv">Author, publication date, geographical area (region and/or subregion), study period, ages, year (or midpoint of range), total population, data type (incidence or prevalence), rate type (crude or standardized), rate of UC, CD and/or IBD-unclassified (IBD-u) and case counts were extracted from each selected study.</s><s xml:id="_rBaktsh">Aggregate rates were removed if an annual rate for the mid-period year was available.</s><s xml:id="_4THDkva">Missing population values were pulled from publicly available official statistical records <ref type="bibr">[53]</ref><ref type="bibr" target="#b60">[54]</ref><ref type="bibr" target="#b61">[55]</ref><ref type="bibr" target="#b62">[56]</ref><ref type="bibr" target="#b63">[57]</ref><ref type="bibr">[58]</ref><ref type="bibr" target="#b64">[59]</ref><ref type="bibr" target="#b65">[60]</ref><ref type="bibr" target="#b66">[61]</ref> .</s><s xml:id="_64Q3DnU">For incidence data, we calculated the summed population for the time period; for prevalence data, we recorded the population at a given timepoint or used the mid-period population in cases of period prevalence.</s><s xml:id="_gGzBK3x">Data extraction and verification were conducted by at least two reviewers.</s><s xml:id="_5XPdXxx">In cases of disagreement between reviewers, consensus was reached through discussion.</s></p><p xml:id="_fCTjXtV"><s xml:id="_MUVyAkN">Quality assessment.</s><s xml:id="_dPnp5Mt">The quality of each study was independently assessed by two reviewers using a modified Joanna Briggs Institute Checklist for Prevalence Studies <ref type="bibr" target="#b67">62</ref> .</s><s xml:id="_W6GbHNs">An additional quality measure was included to identify studies that were strictly population-based (that is, those that identified the entire population sample).</s><s xml:id="_dt5X2qR">Studies that used a representative sample or may have missed some cases due to the sampling method were of lower quality.</s><s xml:id="_3SfXSyA">The results of the quality assessment are presented in Supplementary Table <ref type="table">4</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_thw2HGr">Data verification.</head><p xml:id="_KeG2XB2"><s xml:id="_Vg54zTY">All steps of the systematic review (abstract review, full-text review, data extraction, quality assessment) were conducted by at least two members of a trained centralized team at the University of Calgary to ensure methodological consistency.</s><s xml:id="_ygF8yNT">Additional data verification occurred through international partners from the International Organization for the study of IBD (IOIBD) and the Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) consortium.</s><s xml:id="_xzw48Ej">Experts from IOIBD and GIVES-21 confirmed the inclusion of studies, verified data accuracy and suggested additional studies that may have been missed (Supplementary Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_Xp5EMaS">They confirmed the population-based status of the studies, addressed conflicts in language translation and provided local context (for example, study quality), including explanations for outlier results.</s></p><p xml:id="_SJPdN6R"><s xml:id="_qBmrwXs">Rate calculation.</s><s xml:id="_5j3aS9B">Crude incidence or prevalence was calculated from case counts and the population of the catchment area.</s><s xml:id="_yCCTsyw">If case counts were not provided or the population of the catchment area was not available, we used the rates reported in the papers, whether presented in text, tables or extracted from plots using OriginPro 63 or juicr <ref type="bibr" target="#b69">64</ref> .</s></p><p xml:id="_egPv8Pe"><s xml:id="_WcTGn5Q">Temporal data analysis.</s><s xml:id="_q7wJmjk">When multiple studies overlapped in region and time, we averaged rates to create a single value for that region and year.</s><s xml:id="_BA83GGn">Data preprocessing for analysis and visualization of decade-level rates involved weighting the mean rates calculated by region for each year according to the population of that area for that year.</s><s xml:id="_dfUVECr">Weighted rates were aggregated by decade.</s><s xml:id="_c4AGP6C">This weighting method enabled us to combine regional and subregional data to generate a single value for a region in a particular decade.</s><s xml:id="_CCjXa4c">Aggregated subregional data were treated as representative for a region when no other regional data were available.</s><s xml:id="_u9yQY6k">Missing case counts were back-calculated from provided per 100,000 values and populations.</s><s xml:id="_jJPEavW">In rare cases in which the catchment area population values were not available, non-weighted means were used in the aggregation.</s><s xml:id="_g9PEdxP">When IBD-u was reported separately, it was combined with UC.</s></p><p xml:id="_v8MmwC5"><s xml:id="_5x34wk3">Temporal trends for studies and regions that reported at least three datapoints within a 5-year period were established using Poisson regression (or, if overdispersed, negative binomial regression) models built in R <ref type="bibr">65</ref> , with the year as the sole predictor variable and the incidence rate of either CD or UC as the outcome.</s><s xml:id="_rR9FDUg">We determined the average annual percentage change with associated 95% CI for incidence by exponentiating the β coefficients from the regression models (Supplementary Table <ref type="table">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_DH84Uuw">Machine-learning classification</head><p xml:id="_SFDgSfp"><s xml:id="_gFKePbY">Exploratory data analysis.</s><s xml:id="_63gwjZc">We visually inspected scatterplots of historical trends in incidence and prevalence for early industrialized, newly industrialized and emerging regions to determine epidemiologic stages for a subset of regions with data extracted during the systematic review.</s><s xml:id="_NKp7KdR">On the basis of the assumption that Canada, the United States, most of western Europe, Australia and New Zealand are currently in stage 3, we assigned stage classifications to approximately 65% of our dataset (Supplementary Fig. <ref type="figure" target="#fig_0">16</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_pFkYFV2">k-nearest-neighbors-assisted labelled dataset creation.</head><p xml:id="_WR7FZKG"><s xml:id="_BzxXcJe">As regions and subregions do not transition between stages simultaneously, we built a k-NN classification algorithm to support manual data labelling.</s><s xml:id="_Pwkx3wZ">The k-NN algorithm facilitated an iterative labelling process by classifying regions with robust historical incidence or prevalence data into one of three classifications: stage 1, stage 2 or stage 3. Owing to skewed class proportions (that is, scarcity of stage 1 data) and missing values within classes, we developed four separate models: incidence of CD, incidence of UC, prevalence of CD and prevalence of UC.</s><s xml:id="_UY9fsbn">Each model used two features: incidence or prevalence and the absolute difference in incidence or prevalence from the previously available year of data.</s></p><p xml:id="_wCknMfS"><s xml:id="_pppfqMw">A 75/25 train/test split (n = 1,581/n = 527) was applied.</s><s xml:id="_fU97Jng">The value of k-neighbours was set to the square root of the number of instances in the training data and adjusted accordingly for each model.</s><s xml:id="_Jk5b7sm">A Monte Carlo simulation with 1,000 sampling loops was run for each model.</s><s xml:id="_DH2Ce2X">The model accuracy (Supplementary Table <ref type="table">5</ref>) was determined using the following formula:</s></p><formula xml:id="formula_0">      M L acc(%) = 100 × ( 1)</formula><p xml:id="_3g8VwZm"><s xml:id="_jrfFXNw">where M equals the number of misclassifications (that is, instances in which the model's classification output differed from our manual classification) and L equals the number of Monte Carlo sampling loops.</s><s xml:id="_bcZ2z8z">Three iterations were performed in which the k-NN model output was inspected with successive relabelling of the input data, achieved through consensus among three analysts.</s><s xml:id="_MsnmzK4">At each iteration, additional regions and subregions were added to the labelled dataset until approximately 80% of our total dataset was labelled, with the intention of using it for training and validating a random-forest classifier.</s></p><p xml:id="_3eybAar"><s xml:id="_javBEcE">Random-forest classifier.</s><s xml:id="_FMcwbs6">A random-forest classifier was built in R <ref type="bibr">65</ref> using the randomForest 66 package.</s><s xml:id="_Pd8DY9M">Random forests use an ensemble learning method, in which a specified number of decision trees is generated, and the results are aggregated.</s><s xml:id="_86ea3KZ">The class selected by the model most frequently becomes the resulting classification <ref type="bibr" target="#b17">18</ref> .</s><s xml:id="_Ewf2t79">Each individual decision tree determines a class prediction based on a random subset of features, which reduces the likelihood of overfitting and improves the accuracy of class prediction <ref type="bibr" target="#b72">67</ref> .</s><s xml:id="_7qKeuzq">Random-forest classifiers do not require data scaling and are robust to outliers and noise, which is essential given the heterogeneity and imbalance in our dataset and the complexity of analysing systematic review data.</s><s xml:id="_gQwQTsm">Imputation was used to ensure that a value was specified for each of the primary eight features.</s><s xml:id="_XQMVKPY">Imputation was conducted within a single region across all available datapoints for that region.</s><s xml:id="_3khzwxg">When at least two datapoints were available for a region, linear interpolation was used, using the next observation carried backward and the last observation carried forward to extrapolate missing values outside the available interval.</s><s xml:id="_zAFE6RT">In cases in which only a single datapoint was available for a region, that value was extrapolated to all missing data for that region.</s><s xml:id="_bvvdwpG">Zero imputation was applied to the remaining missing datapoints.</s><s xml:id="_fEYumtb">Features 5-8 were included to account for the potential increase or decrease in incidence and prevalence over time.</s><s xml:id="_nzbThgg">As classifications were made by the random-forest model at the level of the region and year, and many regions lacked incidence or prevalence values for certain years, features 9-16 were included so the random-forest classifier could account for unavailable data that were imputed for classification purposes.</s></p><p xml:id="_GFH7Dnj"><s xml:id="_3qQ5Cu5">Random-forest models provide a measure of feature importance, allowing for an examination of which data types (incidence or prevalence) and which disease types (CD or UC) contributed most to the classifications across the three stages (Supplementary Fig. <ref type="figure" target="#fig_6">20)</ref>.</s></p><p xml:id="_2qEjpJc"><s xml:id="_uPvB4qd">Training, validation and model architecture.</s><s xml:id="_jxWv7cQ">The random-forest model was trained using a subset of data from the labelled dataset (n = 1,647).</s><s xml:id="_d6Ag5Nd">Training and validation sets were created using a 75/25 split (n = 1,235/n = 412) of the labelled dataset, with the out-of-bag (OOB) error estimate used to tune model hyperparameters: ntree (number of trees aggregated) and mtry (number of features used at each split in the tree).</s><s xml:id="_y8vyP5S">The model with the smallest OOB error estimate (OOB = 4.86%) used ntree = 1,000 and mtry = 5 (out of 16 possible features).</s><s xml:id="_efDmbXb">The random-forest's classification accuracy on the unseen validation data was 95.15% (95% CI = 92.60-97.01);</s><s xml:id="_GXDrxxx">this means that the random forest correctly classified a region-year as stage 1, stage 2 or stage 3 approximately 95% of the time, indicating an appropriate model fit and performance (Supplementary Table <ref type="table">6</ref>).</s></p><p xml:id="_BQgrAuS"><s xml:id="_QyCt4WY">Random-forest output.</s><s xml:id="_XAWdVA4">The output from the random-forest model was used to assign an epidemiologic stage to regions with limited incidence and prevalence data (n = 842), resulting in a complete dataset with stage classifications for all regions in the dataset across time (n = 2,489).</s><s xml:id="_FzyJeah">As classifications were based on a single year of data, a decade-level stage classification for a region was calculated by identifying the mode class label from the random-forest model output for years within a decade.</s><s xml:id="_wn7u4pa">In cases in which the model provided an even split of stage classifications for a region within a decade (n = 2: Poland, 2010s; China, 2020s), four expert reviewers assessed available incidence and prevalence data and manually assigned a stage classification for that decade.</s><s xml:id="_3pfGa7W">When no regional data were available, the stage classification for a region was determined based solely on subregional data.</s></p><p xml:id="_qscf4cq"><s xml:id="_NChEBMW">Coalescing ranges.</s><s xml:id="_mfwHVqU">The distribution of incidence and prevalence data for each stage was derived from the machine-learning models and used to calculate CRs, defined by the 25th and 75th percentiles.</s><s xml:id="_Q6rEpN5">Negative binomial regression models followed by post hoc comparisons of estimated marginal means using the emmeans <ref type="bibr" target="#b73">68</ref> package in R with Tukey adjustment for multiple comparisons were used to evaluate significant differences in CR between stage 1, stage 2 and stage 3 in each of the following: CD incidence, UC incidence, CD prevalence and UC prevalence.</s></p><p xml:id="_aGUGSRK"><s xml:id="_DBFey6W">Ulcerative colitis/Crohn's disease ratio.</s><s xml:id="_a3aaYHY">To calculate the UC:CD ratio, the annual population-weighted mean UC incidence was divided by the annual population-weighted mean CD incidence and assigned an epidemiologic stage on the basis of the output of the machine-learning model.</s><s xml:id="_bv8a6ek">The association between UC:CD ratio and epidemiologic stage was modelled using negative binomial regression.</s><s xml:id="_aQETtAa">Pairwise comparisons between the stages were performed using the emmeans <ref type="bibr" target="#b73">68</ref> library in R, with estimated marginal means using Tukey adjustment for multiple comparisons.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RyVcHzG">Societal indicators.</head><p xml:id="_te5mAx3"><s xml:id="_3g8cDHQ">Five societal indicators were examined in relationship to epidemiologic stages: the AHDI, obesity rate, percentage urbanization, the Universal Health Coverage Service Coverage Index (UHC) and the WDI.</s><s xml:id="_BRTBzB8">AHDI is an index score (0-1) that captures the geometric mean of normalized life expectancy, mean years of education, gross domestic product (GDP) per capita and Varieties of Democracy's Liberal Democracy Index <ref type="bibr" target="#b19">20</ref> .</s><s xml:id="_z5YhJu5">AHDI is available in 5-year increments, for which we performed inner-linear interpolation to achieve annual measures.</s><s xml:id="_PfTeeNV">Obesity data were extracted from the WHO database, providing a measure of the percentage of an adult population with a BMI &gt; 30 kg m -2 (ref.</s><s xml:id="_mAKnvzk">69).</s><s xml:id="_ASP32zD">Percentage urbanization data were extracted from a United Nations database, providing a measure of the mid-year percentage of a population living in an urban setting <ref type="bibr" target="#b75">70</ref> .</s><s xml:id="_q9DWgvQ">UHC is an index score (0-100) that quantifies various aspects of healthcare, including reproductive health (for example, the percentage of pregnant people with ≥4 prenatal care visits), prevention of communicable diseases (for example, the percentage of 1-year-old children with adequate diphtheria, tetanus and pertussis vaccination), non-communicable diseases (for example, the percentage of cervical cancer screening in women aged 30-49 years) and healthcare access (for example, the number of hospital beds per capita) <ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_SYYztWu">The UHC is also available in 5-year increments, for which we performed an inner-linear interpolation to achieve annual measures.</s><s xml:id="_u6m7gky">WDI is an index score (0-1) calculated by dividing the available calories per person per day from animal oils and fats, milk, eggs, plant oils and fats, and sugars by the total available calories per person per day, similar to the methodology provided by Azzam in 2021, extended to all regions within our dataset <ref type="bibr" target="#b23">24</ref> .</s><s xml:id="_ZuJDbZt">Regional calorie availability was extracted from the Food Balance sheets published by the Food and Agriculture Organization <ref type="bibr" target="#b76">71</ref> .</s></p><p xml:id="_zNf7Dg3"><s xml:id="_9tnG9dM">Time-and region-specific values from each of these five indicators were stratified by the three epidemiologic stages (as derived by the machine-learning classifier) and statistically compared across stages using Kruskal-Wallis nonparametric tests with post hoc comparisons using Wilcoxon rank-sum tests with adjustment for multiple comparisons.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_CJMbHeJ">Modelling stage 4 using PDEs</head><p xml:id="_KaSbMxC"><s xml:id="_Kzx3nsr">To explore the potential growth characteristics of IBD prevalence in stage 3 regions, we modelled the time-dependent prevalence using historic prevalence and incidence data, plus population projections from Canada, Denmark and Scotland (Lothian).</s><s xml:id="_GfDB9Ce">Calculations were completed using Mathematica (v.13.1) <ref type="bibr" target="#b77">72</ref> .</s></p><p xml:id="_Q2rJ3Xb"><s xml:id="_rdh6PsQ">Data sources.</s><s xml:id="_GCsVaCE">Incidence and prevalence of IBD were calculated for Canada, Denmark and Scotland (Lothian) from administrative data provided by each region (Supplementary Table <ref type="table">7</ref>).</s></p><p xml:id="_fVYX3AA"><s xml:id="_Gk8xUVq">For Canada, population-based provincial administrative healthcare data were combined from Alberta, British Colombia, Manitoba, Newfoundland and Labrador, Nova Scotia, Ontario, Quebec and Saskatchewan to capture data for 2007-2014 <ref type="bibr" target="#b14">15</ref> .</s><s xml:id="_jXXCHmX">In Denmark, nationwide individual-level healthcare information was obtained from the Danish National Patient Register for 2010-2017 (ref.</s><s xml:id="_ekh7tEU">73).</s><s xml:id="_D7QkJ7A">For Scotland, data for the Lothian region (Edinburgh and surrounding area) were sourced from TrakCare (InterSystems) electronic health records for 2010-2017 <ref type="bibr" target="#b12">13</ref> .</s><s xml:id="_6wtbJde">Projections of the population age-distribution for 2018-2043 were gathered from Statistics Canada 26,53 , Denmark <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b79">74</ref> and Scotland (Lothian) <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b75">70</ref> (Supplementary Fig. <ref type="figure" target="#fig_6">21</ref>).</s></p><p xml:id="_BSy9S2W"><s xml:id="_fDHvFjp">Region-specific data transformations.</s><s xml:id="_Jjh7F4N">Raw historic prevalence, incidence and population data for Canada, Denmark and Scotland (Lothian) were transformed.</s><s xml:id="_b3WgAt5">All age categories (&lt;10 years, 10-17, 18-24, 25-34,  35-44, 45-54, 55-64, 64-79, 80+) were closed, with an upper and lower bound, except for the highest age category (80+), for which the centre of the age bin was set to the estimated population-averaged mean value (86 years for 80+, 93 years for 90+ and 106 years for 105+).</s><s xml:id="_Qme5EAG">The prevalence up to age 110 was estimated using linear extrapolation, constrained to have a zero or negative slope, and to be equal to or greater than zero, while the historic incidence and population projections were set to zero at age 110.</s></p><p xml:id="_vcNAMJd"><s xml:id="_PCWVrPj">Deriving the equation.</s><s xml:id="_mF8RwXn">The change in prevalence over time was modelled using a PDE <ref type="bibr" target="#b80">75,</ref><ref type="bibr" target="#b81">76</ref> that has previously been used to estimate the future prevalence of chronic diseases, including diabetes mellitus <ref type="bibr" target="#b82">77,</ref><ref type="bibr" target="#b83">78</ref> and dementia <ref type="bibr" target="#b24">25</ref> .</s><s xml:id="_jjdpDw4">The PDE is derived from a compartment model <ref type="bibr" target="#b80">75,</ref><ref type="bibr" target="#b81">76</ref> (Supplementary Fig. <ref type="figure" target="#fig_6">22</ref>) and has widespread applicability to diseases where the incidence rate is known or can be modelled.</s></p><p xml:id="_uF8CunM"><s xml:id="_wMtyuW7">The prevalence of a disease p depends on both time t and the age distribution of the disease cohort a.</s><s xml:id="_m7qCv4y">The change in prevalence as a function of both time and age is modelled by equation ( <ref type="formula" target="#formula_1">2</ref>) <ref type="bibr" target="#b24">25</ref> :</s></p><formula xml:id="formula_1">      p t p a p i m p R p R r p μ ∂ ∂ + ∂ ∂ = (1 -) - ( -1) ( -1) + 1 - +<label>(2)</label></formula><p xml:id="_8JhPtSe"><s xml:id="_vfBUNb9">Here,</s></p><formula xml:id="formula_2">p t ∂ ∂ and p a ∂ ∂</formula><p xml:id="_ppwhv3m"><s xml:id="_uHnfNzC">are the partial derivatives of prevalence with respect to time and age.</s><s xml:id="_aYT6DEs">The incidence rate i, full population mortality rate m, relative mortality ratio R (ratio of those with the disease to those without) and recovery rate r are all functions of both time and age.</s><s xml:id="_BJAhpkG">The migration term μ is a function of time, age and prevalence.</s></p><p xml:id="_zEFUjhF"><s xml:id="_yT279sJ">Simplifying the equation.</s><s xml:id="_eCXahxd">For parsimony, we neglect terms in equation (2) that are not applicable or are small enough to be ignored.</s><s xml:id="_PK7A89C">IBD is a chronic, incurable disease and we therefore ignored the recovery rate, r.</s><s xml:id="_4fXrkzQ">The mortality term, m p(R - 1)/[p(R - 1) + 1] was set to zero owing to the relatively small difference in life expectancy between those living with IBD and the general population <ref type="bibr" target="#b84">79</ref> .</s><s xml:id="_5E9mAht">Similarly, the migration term, μ, was set to zero because immigration to the regions being examined greatly exceeds the emigration <ref type="bibr">[80]</ref><ref type="bibr" target="#b86">[81]</ref><ref type="bibr" target="#b87">[82]</ref> , and the prevalence of IBD is lower in new immigrants than in the existing population <ref type="bibr" target="#b88">83,</ref><ref type="bibr" target="#b89">84</ref> .</s><s xml:id="_4rWe7C4">Omitting these three terms yields the simplified equation</s></p><formula xml:id="formula_3">p t p a p i t a ∂ ∂ + ∂ ∂ = (1 -) ( , )<label>(3)</label></formula><p xml:id="_JAv8GEB"><s xml:id="_MMKxVej">which makes explicit the age and time dependence of the incidence.</s></p><p xml:id="_9zMRPVj"><s xml:id="_gpVM8qh">Solving the equation.</s><s xml:id="_UGR2KVz">Given the age distribution of prevalence at an initial time, p 0 (a), and assuming that the prevalence must be zero at age zero, equation ( <ref type="formula" target="#formula_3">3</ref>) is solved using the method of characteristics <ref type="bibr" target="#b90">85</ref> to yield ∫ ∫ p t a p a t ta a t ( , ) = 1 -[1 -( -)]e , 0≤ &lt; 1 -e , 0 ≤ &lt; (4) i x x t a x i x a t x x 0 -( , + -)d -( + -, )d t a 0 0        To calculate prevalence as a function of time, we multiply by the normalized population age-distribution σ(a) and integrate over age, such that ∫ p t p t a σ a da ( ) = ( , ) ( ) (5) 0 ∞ Equation (5) allows us to extrapolate the prevalence of IBD over the coming decades.</s><s xml:id="_hU72m3Y">To do so, three additional pieces of information are required: the initial prevalence of IBD as a function of age, the incidence rate of IBD as a function of age and time, and projections of the population age distribution.</s><s xml:id="_YQnJ8qz">Age-dependent IBD incidence and prevalence.</s><s xml:id="_xX6WV8N">A linear interpolation of the age-dependent IBD prevalence data for Canada (2014), Denmark (2017) and Scotland (2017) served as the initial prevalence, p 0 (a), for modelling (Supplementary Fig. 23).</s><s xml:id="_2gkYSYZ">Data for IBD incidence during 2007-2014 for Canada and 2010-2017 for Denmark and Scotland were compiled (Supplementary Fig. 24), with the average incidence from these 8 years serving as the age-dependent component of the model incidence rate, f(a).</s><s xml:id="_3MCVPAq">A time-dependent component was added to the incidence, modelled as an exponential growth process with growth rate g: i t a f a ( , ) = ( )e (6) t×ln( ) g Model verification.</s><s xml:id="_jMnkV9c">To verify that our model describes the prevalence of IBD, we compared the model's output to historical data, specifically the age-structured prevalence from 2014 for Canada and 2017 for Denmark and Scotland.</s><s xml:id="_6ZqVB6u">Starting with equation (4), p 0 (a) was taken as the age-structured prevalence from 2002 (Canada), 2010 (Denmark) and 2009 (Scotland), and a time-independent incidence rate f(a) as the average over the years 2007-2014 (Canada) or 2010-2017 (Denmark and Scotland) (Supplementary Figs.</s><s xml:id="_JKny4j4"><ref type="figure" target="#fig_6">23</ref> and <ref type="figure" target="#fig_6">24</ref>).</s><s xml:id="_gs6kEsE">For Canada, the model produced a 2014 prevalence of 0.65%, compared with the observed 0.65% (Supplementary Fig. <ref type="figure" target="#fig_6">25a</ref>).</s><s xml:id="_CjbUXK2">For Denmark, the model produced a 2017 prevalence of 0.98%, compared with the observed 0.94% (Supplementary Fig. <ref type="figure" target="#fig_6">25b</ref>).</s><s xml:id="_GKcfStf">For Scotland, the model produced a 2017 prevalence of 0.88%, compared with the observed 0.79% (Supplementary Fig. <ref type="figure" target="#fig_6">25c</ref>).</s><s xml:id="_dttTrm6">The high degree of concordance suggests that the simplified model is reasonably accurate for longer-term modelling of general prevalence trends.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2ujhkTH">Slopes and central difference approximations.</head><p xml:id="_rYKc8C9"><s xml:id="_pH4pJN6">Central difference approximations to the slope of the time-dependent IBD prevalences in Canada, Denmark, and Scotland were calculated to determine the percent change in prevalence for each year of data.</s><s xml:id="_EncRSeR">The central difference approximations is calculated by:</s></p><formula xml:id="formula_4">δp x p t h p t h h ( ) = ( + ) -( -) 2<label>(7)</label></formula><p xml:id="_sFWwxbx"><s xml:id="_xvFhW3S">where p(t) is the prevalence at year t, and h is the time-step, set equal to 1 year (that is, the frequency with which the time-dependent prevalence was calculated).</s><s xml:id="_xC6SE5Q">Central difference approximations were averaged over 5-year periods to determine whether Canada, Denmark or Scotland had reached prevalence equilibrium by 2043.</s></p><p xml:id="_c8U5Xsx"><s xml:id="_JFG5Dvd">Yearly incidence change scenarios.</s><s xml:id="_3Z7cMcu">We selected five values of the growth constant g in equation ( <ref type="formula">6</ref>): 0.98, 0.99, 1.00, 1.01 and 1.02, corresponding to 2% and 1% incidence rate decreases per year, no change, and 1% and 2% incidence growth per year, respectively.</s><s xml:id="_wHFt6FR">To model current trends, we assume that the incidence rate is constant, as per the 2007-2014 (Canada) and 2010-2017 (Denmark and Scotland) observed data, until 2024 at which time the exponential increases or decreases in incidence begin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_H6Yg5FS">Strengths and limitations</head><p xml:id="_esQRxQy"><s xml:id="_Wq3Ps9H">This study represents, to our knowledge, the most comprehensive summation of population-based data on the incidence and prevalence of IBD, spanning a century of historical data that was used to explore spatial and temporal epidemiologic patterns across the world.</s><s xml:id="_DsPszz8">We used a unique machine-learning approach to classify regions into three epidemiologic stages over time and established benchmarks to define incidence and prevalence ranges for each stage.</s><s xml:id="_URv9ZEr">Furthermore, to our knowledge, this is the first study to model the transition to a theoretical fourth stage, where prevalence growth plateaus due to an ageing IBD population and stable incidence rates.</s><s xml:id="_JgEsYg8">However, the interpretation of our findings should be evaluated in the context of inherent limitations.</s><s xml:id="_sDB3sNN">We relied on incidence and prevalence data that varied in quality.</s><s xml:id="_A9mWF2a">Historical data from the twentieth century, regions lacking healthcare surveillance systems and fractionated healthcare systems that impair population-based case capture were of lower quality, leading to heterogeneity in the reported data.</s><s xml:id="_UtsFSWB">To address this, we conducted a quality assessment of each paper through a centralized evaluation process, which was further complemented by assessment from regional experts.</s><s xml:id="_tfkG2Ck">Regions with administrative healthcare databases can electronically capture IBD cases using coding algorithms (for example, ICD coding); however, validation studies have demonstrated misclassification errors that lead to the inclusion of false positives, potentially inflating incidence and prevalence.</s><s xml:id="_bnuchDD">By contrast, regions without population-based electronic healthcare surveillance systems relied on medical registries to identify IBD cases.</s><s xml:id="_hunzpRV">While this approach results in highly accurate diagnoses, it may miss cases (for example, milder cases not followed by gastroenterologists), potentially leading to underestimation of incidence and prevalence.</s></p><p xml:id="_GBbauMK"><s xml:id="_9djpmd4">The primary source of inconsistency in our random-forest model arises from the availability epidemiologic data, leading to an imbalance across stage classes.</s><s xml:id="_qR57bKj">The scarcity of data from emerging regions and historical data from the earlier part of the twentieth century resulted in fewer studies available to assess stage 1.</s><s xml:id="_b4SABam">Moreover, data from stage 1 regions, which are predominantly low-income, often lacked electronic surveillance systems to support case identification.</s><s xml:id="_RFy4kzM">Consequently, we allowed case-ascertainment approaches that may have missed IBD cases such as surveying gastroenterology offices or hospital-based capture systems, provided that the hospitals serve a defined catchment area.</s><s xml:id="_prQwSzq">However, in our quality assessment, we differentiated population-based studies that met our strict definition (that is, complete capture of cases in a defined region) from those that did not (that is, a representative sample).</s><s xml:id="_qhr5Uns">Our repository (<ref type="url" target="https://kaplan-gi.shinyapps.io/GIVES21/">https://kaplan-gi.shinyapps.io/GIVES21/</ref>)</s><s xml:id="_9pnS7Ep">allows users to subset data by these two categories of population based.</s></p><p xml:id="_6JjDePb"><s xml:id="_REEsxBQ">Regional data are missing or limited in many highly populated areas in Africa, Asia and Latin America.</s><s xml:id="_r6kyFvG">Our machine-learning classifier was trained on robust data, enabling us to reliably classify regions during different time periods when data are scarce.</s><s xml:id="_Ur43bMn">Moreover, our GIVES-21 consortium is currently conducting high-quality, population-based epidemiologic research in over 30 regions with limited IBD data from newly industrialized and emerging regions <ref type="bibr" target="#b32">33</ref> .</s><s xml:id="_Hfv6n4e">Our repository (https:// kaplan-gi.shinyapps.io/GIVES21/) is being continuously updated to allow for integration and reanalyses of global epidemiologic data as new information is available.</s><s xml:id="_nkWQAyD">To capture the most recent population-based data available, data from 2020-2024 were included as a partial decade in our analyses.</s><s xml:id="_xp9eK4B">Although this period does not provide a complete decade for stratifying stage classification, its inclusion highlights the best estimate of the current burden of IBD in regions where these years of data are available.</s></p><p xml:id="_UnyxrRZ"><s xml:id="_gtyQZSv">While the model was highly accurate (&gt;95%) in classifying regions into one of three stages, a few regions exhibited unexpected classifications: Ireland was classified as stage 2 during 2010-2019, which contrasts with other contemporary regions in Western Europe.</s><s xml:id="_9yCxCYW">Deviations between the model's output and expected classifications were primarily observed in regions transitioning between stages, especially in cases in which there was a lack of comprehensive data or when subregional data were used in place of regional values.</s><s xml:id="_sS88ZP5">For example, Ireland's classification for 2010-2019 was based on data from County Meath in 2010 <ref type="bibr" target="#b91">86</ref> .</s><s xml:id="_Y6kKwnK">These discrepancies highlight the need for more recent, population-based studies in such regions to improve the classification accuracy and refine estimates.</s></p><p xml:id="_9rE79Eh"><s xml:id="_Zf5Qecy">Our PDE models were developed with model parsimony in mind, and so did not include the differential mortality between the IBD and non-IBD populations; this implies that the projections serve as a likely upper bound on the future IBD prevalence.</s><s xml:id="_5XDJDTM">Furthermore, our classifier and PDE models did not directly account for immigration.</s><s xml:id="_sz9sDdH">Research shows that individuals immigrating from stage 1 or 2 regions to a stage 3 region eventually assume the IBD risk of their host region, particularly among the first-degree offspring <ref type="bibr" target="#b88">83,</ref><ref type="bibr" target="#b89">84</ref> .</s><s xml:id="_rxW2Knb">Finally, we acknowledge that unexpected future events may influence future projections.</s><s xml:id="_eEVgXZw">For example, we varied incidence growth in the model within a range of +2% to -2% over a 20-year horizon; however, events that could result in a more substantial change in incidence (such as the discovery of an IBD cure, or a high-mortality pandemic) are not accounted for in our model.</s><s xml:id="_drUeS9S">Moreover, we limited our analyses to three regions currently in stage 3 to predict the transition towards stage 4. Future research that includes data from other stage 3 regions are needed to ensure generalizability of these predictions.</s></p><p xml:id="_beTMRhB"><s xml:id="_G2gaBBF">Extended Data Fig. <ref type="figure" target="#fig_0">1</ref> | Density of all incidence data included in the systematic review for Crohn's disease and ulcerative colitis across regions and time.</s><s xml:id="_Px9YQPY">All data are represented in violin plots with boxplot overlays where the middle line on the boxplot is the median, the lower hinge on the boxplot is the 25 th percentile (i.e., first quartile), the upper hinge on the boxplot is the 75 th percentile (i.e., third quartile); the violin is the data density at the associated value on the y-axis, and points are individual data points outside of the density distribution.</s><s xml:id="_JghraYU">Incidence rates of Crohn's disease or ulcerative colitis that exceed the ceiling threshold of 40 per 100,000 are considered outlier data.</s><s xml:id="_jf89ktX">All data are represented in boxplots where the middle line is the median, the lower hinge is the 25 th percentile (i.e., first quartile), the upper hinge is the 75 th percentile (i.e., third quartile), the lower whisker extends to 1.5 × the interquartile range (IQR) from the first quartile, the upper whisker extends to 1.5 × IQR from the third quartile, and the data points beyond the end of the whiskers are individually plotted outliers.</s><s xml:id="_NBwpSqK">A Kruskal-Wallis non-parametric test with post hoc comparisons using Wilcoxon rank-sum adjusted for multiple comparisons showed significant differences between epidemiologic stages for AHDI, obesity rate, UHC Service Index, percent urbanization, and Western Diet Index (p &lt; 0.001 for all comparisons).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2VSGkPS">Extended</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zTrY22F">Extended Data Table 2 | Percent change in prevalence slope in 2042 by yearly incidence rate change</head><p xml:id="_3YPyZZw"><s xml:id="_WKj2Tky">Slopes calculated using central difference approximation, for modelled yearly incidence rate changes of 2% decrease, 1% decrease, no change, 1% increase, and 2% increase.</s><s xml:id="_7eRPpm3">We propose that stage 4-Prevalence Equilibrium-occurs when the change in the slope of prevalence decelerates to an average of 0% (±0.01%).</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 |</head><label>1</label><figDesc><div><p xml:id="_mdgQqY5"><s xml:id="_aGm5CPX">Fig. 1 | The incidence (per 100,000 person-years) and prevalence (per 100,000) of IBD by decade and region.</s><s xml:id="_zQnXpMh">a, The incidence of CD by decade, with regions ranked from the highest (top) to lowest (bottom) most recent median incidence value available.</s><s xml:id="_3U5mEek">b, The incidence of UC by decade, with regions ranked from the highest (top) to lowest (bottom) most recent median incidence value available.</s><s xml:id="_K8ahssd">c, The prevalence of CD by decade, with regions ranked from the highest (top) to lowest (bottom) most recent median prevalence value available.</s><s xml:id="_k7TYgWq">d, The prevalence of UC by decade, with regions ranked from the highest (top)to lowest (bottom) most recent median prevalence value available.</s><s xml:id="_4rGYfrt">Colour saturation represents median incidence/prevalence, calculated from all studies within a given region for that decade.</s><s xml:id="_46Jt5Yy">CR values (25th to 75th percentiles) of incidence/prevalence for the corresponding region-decade pairing are provided in Supplementary Fig.2.</s><s xml:id="_BECKAKU">All data are available at Figshare (https://doi.org/10.6084/ m9.figshare.24952557).</s><s xml:id="_mD4kkWh">An interactive map depicting year-over-year changes in incidence and prevalence is available online (https://kaplan-gi.shinyapps.io/ GIVES21/).</s><s xml:id="_jDNHVYC">Regions are labelled with their International Organization for Standardization (ISO) 3166-1 alpha-3 codes: Algeria (DZA), Argentina (ARG),</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>3 Fig. 2 |</head><label>32</label><figDesc><div><p xml:id="_KCzWFfM"><s xml:id="_5R2F4K9">Fig. 2 | CRs of CD and UC across epidemiologic stages 1, 2 and 3. a, The CR-I of CD (left) and UC (right) across the three epidemiologic stages.</s><s xml:id="_wfn437h">Number of observations: n = 263 (CD stage 1), n = 1,011 (CD stage 2), n = 796 (CD stage 3), n = 277 (UC stage 1), n = 847 (UC stage 2), n = 760 (UC stage 3).</s><s xml:id="_z3chbE5">b, The CR-P of CD (left) and UC (right) across the three epidemiologic stages.</s><s xml:id="_VBt3syj">Number of observations: n = 86 (CD stage 1), n = 247 (CD stage 2), n = 443 (CD stage 3), n = 118 (UC stage 1), n = 238 (UC stage 2), n = 435 (UC stage 3).</s><s xml:id="_UCJZcty">Data are categorized by type (incidence/prevalence), disease type (CD/UC) and epidemiologic stage(stage 1, stage 2, stage 3), as determined by the random-forest classifier.</s><s xml:id="_8MDaT7s">For the box plots, the centre line shows the median, the lower hinge shows the 25th percentile (that is, first quartile) and the upper hinge shows the 75th percentile (that is, third quartile).</s><s xml:id="_SCYUWKU">The 25th and 75th percentiles are labelled and correspond to the CRs.</s><s xml:id="_dZRxtWP">Statistical analysis was performed using negative binomial regression with post hoc comparisons of estimated marginal means with Tukey adjustment for multiple comparisons, showing significant differences between all stages for the incidence and prevalence of CD and UC (P &lt; 0.001 for all comparisons).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 |</head><label>3</label><figDesc><div><p xml:id="_CMR5qJ3"><s xml:id="_jFGpH5s">Fig. 3 | Global maps depicting epidemiologic stages of IBD evolution from 1950 to 2024.</s><s xml:id="_P5CnwUG">a, Epidemiologic stages from 1950 to 1959.</s><s xml:id="_dKdSesw">b, Epidemiologic stages from 1960 to 1969.</s><s xml:id="_9DwZKY9">c, Epidemiologic stages from 1970 to 1979.</s><s xml:id="_cKszZhZ">d, Epidemiologic stages from 1980 to 1989.</s><s xml:id="_aS2aSkz">e, Epidemiologic stages from 1990 to 1999.</s><s xml:id="_mqXT2Ft">f, Epidemiologic stages from 2000 to 2009.</s><s xml:id="_SAh38CM">g, Epidemiologic stages from 2010 to 2019.</s><s xml:id="_hmYfBsX">h, Epidemiologic stages from 2020 to 2024; because regions cannot regress in stage, regions without data in 2020-2024 but with a previous stage 3 classification are shaded in a lighter green than regions in stage 3 that do have data during this period.</s><s xml:id="_dw348F3">Each region is coloured according to its epidemiologic stage as predicted by the random-forest classifier.</s><s xml:id="_4PHJFgN">Interactive maps are available online (https://kaplan-gi.shinyapps.io/GIVES21/).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 |</head><label>4</label><figDesc><div><p xml:id="_bNMjcVR"><s xml:id="_7CVThu7">Fig. 4 | PDE-modelled time-dependent prevalence.</s><s xml:id="_kMqxNuS">a, Modelled timedependent prevalence of IBD in Canada (observed data, 2007-2014), Denmark (observed data, 2010-2017) and Scotland (observed data, 2010-2017).</s><s xml:id="_yGsGPsW">b, Central difference approximations of the slopes of time-dependent IBD prevalence.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 5 |</head><label>5</label><figDesc><div><p xml:id="_AZAt79Y"><s xml:id="_4chkYsU">Fig. 5 | Calculations of IBD prevalence over time under scenarios of incidence rate change.</s><s xml:id="_7AdvNaH">a,The prevalence in Canada under a 2%, 1%, 0%, -1% and -2% change in incidence per year, with the base incidence rate set equal to the average incidence from 2007 to 2014.</s><s xml:id="_y36VNSG">b, The prevalence in Denmark under a 2%, 1%, 0%, -1% and -2% change in incidence per year, with the base incidence rate set equal to the average incidence from 2010 to 2017.</s><s xml:id="_WH68djr">c, The prevalence in Scotland under a 2%, 1%, 0%, -1% and -2% change in incidence per year, with the base incidence rate set equal to the average incidence from 2010 to 2017.</s><s xml:id="_By7wJfp">d, Central difference approximations of the slopes of the time-dependent prevalence in Canada for each of the five yearly incidence rate change scenarios.</s><s xml:id="_HQCvkwh">e, Central difference approximations of the slopes of the time-dependent prevalence in Denmark for each of the five yearly incidence rate change scenarios.</s><s xml:id="_wNTe87f">f, Central difference approximations of the slopes of the time-dependent prevalence in Scotland for each of the five yearly incidence rate change scenarios.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Features</head><figDesc><div><p xml:id="_5tnWyUh"><s xml:id="_dks9ayG">and data imputation.</s><s xml:id="_WNzpNRR">Classifying a region's stage in a particular year was based on 16 possible features: (1) CD incidence; (2) UC incidence; (3) CD prevalence; (4) UC prevalence; (5) rates of change for incidence of CD; (6) rates of change for incidence of UC; (7) rates of change for prevalence of CD; (8) rates of change for prevalence of UC; and (9-16) indicators of imputed values for each of the preceding eight variables.</s><s xml:id="_vuJP38d">The structure of the classifier required a value to be specified for each of the above features for each year of available data by region.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Data Fig. 2 |</head><label>2</label><figDesc><div><p xml:id="_JS88rbs"><s xml:id="_faSSuKX">Annual incidence and prevalence ofCrohn's disease and ulcerative across epidemiologic stages of IBD evolution.</s><s xml:id="_UpEFYCn">a, Annual incidence of Crohn's disease categorized by three epidemiologic stages of IBD evolution as predicted by the random forest classifier.</s><s xml:id="_HeJ3AaA">b, Annual incidence of ulcerative colitis categorized by three epidemiologic stages of IBD evolution as predicted by the random forest classifier.</s><s xml:id="_u5rE7ES">c, Annual prevalence of Crohn's disease categorized by three epidemiologic stages of IBD evolution as predicted by the random forest classifier.</s><s xml:id="_jbnz8fU">d, Annual prevalence of ulcerative colitis categorized by three epidemiologic stages of IBD evolution as predicted by the random forest classifier.</s><s xml:id="_E3S2HVE">Each point corresponds to an annual aggregate mean of CD or UC incidence/prevalence for all regions with available data.</s><s xml:id="_fq7pm6F">Extended Data Fig. 3 | Comparison of societal indicators across three epidemiologic stages.</s><s xml:id="_9TfGGzs">a, Augmented Human Development Index (AHDI) stratified by epidemiologic stage, as predicted by the random forest classifier (number of observations: stage 1 n = 470; stage 2 n = 1,090; stage 3 n = 540).</s><s xml:id="_BwAXVjM">b, Obesity rate stratified by epidemiologic stage, as predicted by the random forest classifier (number of observations: stage 1 n = 295; stage 2 n = 791; stage 3 n = 476).</s><s xml:id="_5626xRG">c, Universal Health Coverage (UHC) Service Index stratified by epidemiologic stage, as predicted by the random forest classifier (number of observations: stage 1 n = 160; stage 2 n = 400; stage 3 n = 380).</s><s xml:id="_Mxvbfyj">d, Percent urbanization stratified by epidemiologic stage, as predicted by the random forest classifier (number of observations: stage 1 n = 460; stage 2 n = 1,180; stage 3 n = 610).</s><s xml:id="_YKMQaT5">e, Western Diet Index (WDI) stratified by epidemiologic stage, as predicted by the random forest classifier (number of observations: stage 1 n = 348; stage 2 n = 980; stage 3 n = 540).</s></p></div></figDesc></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_jXkZfku">Acknowledgements</head><p xml:id="_b9MpSrE"><s xml:id="_c9AwgaQ">This work was conducted by the <rs type="institution">Global Cluster of IOIBD</rs>.</s><s xml:id="_3MSeYzp">The work was funded by <rs type="funder">The Leona M. and Harry B. Helmsley Charitable Trust</rs> (grant no.</s><s xml:id="_waafbTM"><rs type="grantNumber">G-2108-04777</rs>); the <rs type="funder">Canadian Institutes of Health Research</rs>, Project <rs type="grantName">Scheme Operating Grant</rs> (reference no.</s><s xml:id="_YFRTGGP"><rs type="grantNumber">PJT-162393</rs>); and the <rs type="funder">International Organization for the study Inflammatory Bowel Disease (IOIBD)</rs>.</s><s xml:id="_E7AdGas">S.C.N. has received research funding from the <rs type="funder">Research Grants Council-Research Impact Fund</rs> (<rs type="programName">RGC-RIF</rs>, grant no.</s><s xml:id="_Wq7KKCa"><rs type="grantNumber">R4030-22</rs>), <rs type="funder">New Cornerstone Science Foundation</rs> (grant no.</s><s xml:id="_PCtEy9w"><rs type="grantNumber">NCI202346</rs>), <rs type="funder">InnoHK</rs>, The <rs type="funder">Government of Hong Kong, Special Administrative Region of the People's Republic of China</rs>, and the <rs type="funder">Leona M. and Harry B. Helmsley Charitable Trust</rs> (grant no.</s><s xml:id="_wwp8QXB"><rs type="grantNumber">2017PG-IBD003</rs>).</s></p></div>
<div><head xml:id="_3b7Nxes">Article</head><p xml:id="_7zeEJwf"><s xml:id="_sb2m7Sr">Bioepis, <rs type="institution">Fresenius Kabi, Tillotts</rs>, <rs type="funder">Trellus Health and Iterative Health</rs>.</s><s xml:id="_NYVTWC3">B.L. has received speaking fees from <rs type="funder">Tillotts Pharma</rs> and <rs type="funder">Janssen Cilag</rs>; consultancy fees from <rs type="funder">Tillotts Pharma</rs> and <rs type="person">Bristol Myers Squib</rs>; and has received unrestricted research grants from <rs type="funder">Janssen Cilag</rs>, <rs type="funder">Tillotts Pharma</rs>; outside the submitted work.</s><s xml:id="_XSsxsBR">E.V.L. has consulted for <rs type="funder">AbbVie</rs>, <rs type="funder">Alvotech</rs>, <rs type="funder">Amgen</rs>, <rs type="funder">Arena</rs>, <rs type="funder">Astellas</rs>, <rs type="funder">Avalo</rs>, <rs type="funder">Boehringer Ingelheim</rs>, <rs type="funder">Bristol-Myers Squibb</rs>, <rs type="funder">Celltrion</rs>, <rs type="funder">Eli Lilly</rs>, <rs type="funder">Fresenius Kabi</rs>, <rs type="funder">Genentech</rs>, <rs type="funder">Gilead</rs>, <rs type="funder">GlaxoSmithKline</rs>, <rs type="funder">Gossamer Bio</rs>, <rs type="funder">Iota Biosciences</rs>, <rs type="funder">Iterative Health</rs>, <rs type="person">Janssen</rs>, <rs type="person">Morphic</rs>, <rs type="person">Ono</rs>, <rs type="person">Protagonist</rs>, Sun, <rs type="person">Surrozen</rs>, <rs type="person">Takeda</rs>, TR1X and <rs type="institution">UCB</rs>; has received research support from <rs type="funder">AbbVie</rs>, <rs type="funder">AstraZeneca</rs>, <rs type="funder">Bristol-Myers Squibb</rs>, <rs type="funder">Celgene/Receptos</rs>, <rs type="funder">Genentech</rs>, <rs type="funder">Gilead</rs>, <rs type="person">Gossamer Bio</rs>, <rs type="funder">Janssen</rs>, <rs type="funder">Takeda</rs>, <rs type="funder">Theravance</rs> and <rs type="funder">UCB</rs>; and is a shareowner of Exact Sciences.</s><s xml:id="_eT77gqX">S.C.N. has served as an advisory board member for <rs type="institution">Pfizer</rs>, <rs type="institution">Ferring</rs>, <rs type="institution">Janssen</rs> and <rs type="institution">AbbVie</rs> and received honoraria as a speaker for <rs type="funder">Ferring</rs>, Tillotts, <rs type="funder">Menarini</rs>, <rs type="funder">Janssen</rs>, <rs type="funder">AbbVie</rs> and <rs type="institution">Takeda</rs>; has received research grants through her affiliated institutions from <rs type="funder">Olympus</rs>, <rs type="funder">Ferring</rs> and <rs type="funder">AbbVie</rs>; is a founder member, non-executive director, non-executive scientific advisor and shareholder of <rs type="institution">GenieBiome Ltd</rs>; and receives patent royalties through her affiliated institutions.</s><s xml:id="_mszEFkH">S.O. has received speaking fees from <rs type="funder">Mitsubishi Tanabe Pharma</rs> and consulting fees from <rs type="funder">EA Pharma</rs>.</s><s xml:id="_XUKRRVc">O.O. has been PI on projects at <rs type="institution">Karolinska Institutet</rs> partly financed by investigator-initiated grants from <rs type="funder">Janssen</rs>, <rs type="funder">Takeda</rs>, <rs type="funder">AbbVie</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Bristoll Myers Squibb</rs> and <rs type="funder">Ferring</rs>, and also report grants from <rs type="funder">Pfizer</rs>, <rs type="funder">AbbVie</rs>, <rs type="funder">Janssen</rs> and <rs type="funder">Galapagos</rs> in the context of a national <rs type="programName">safety monitoring programs</rs>; none of these studies have any relation to the present study.</s><s xml:id="_8a6bNdu">The <rs type="institution">Karolinska Institutet</rs> has received fees for lectures and participation on advisory boards by <rs type="person">O.O.</rs> from <rs type="funder">Janssen</rs>, <rs type="funder">Ferring</rs>, <rs type="funder">Takeda</rs> and <rs type="funder">Pfizer</rs> on topics not related to the present study.</s><s xml:id="_H2YTpXU">R.P. has received consulting fees from <rs type="funder">Abbott</rs>, <rs type="funder">AbbVie</rs>, <rs type="funder">Alimentiv (formerly Robarts)</rs>, <rs type="funder">Amgen</rs>, <rs type="funder">Arena Pharmaceuticals</rs>, <rs type="funder">AstraZeneca</rs>, <rs type="funder">Biogen</rs>, <rs type="funder">Boehringer Ingelheim</rs>, <rs type="funder">Bristol-Myers Squibb</rs>, <rs type="funder">Celgene</rs>, <rs type="funder">Celltrion</rs>, <rs type="funder">Cosmos Pharmaceuticals</rs>, <rs type="funder">Eisai</rs>, <rs type="funder">Elan</rs>, <rs type="funder">Eli Lilly</rs>, <rs type="funder">Ferring</rs>, <rs type="funder">Galapagos</rs>, <rs type="funder">Fresenius Kabi</rs>, <rs type="funder">Genentech</rs>, <rs type="funder">Gilead Sciences</rs>, <rs type="funder">Glaxo-Smith Kline</rs>, <rs type="funder">JAMP Bio</rs>, <rs type="funder">Janssen</rs>, <rs type="funder">Merck</rs>, <rs type="funder">Mylan</rs>, <rs type="funder">Novartis</rs>, <rs type="funder">Oppilan Pharma</rs>, <rs type="funder">Organon</rs>, <rs type="funder">Pandion Pharma</rs>, <rs type="funder">Pendopharm</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Progenity</rs>, <rs type="funder">Protagonist Therapeutics</rs>, <rs type="funder">Roche</rs>, <rs type="funder">Sandoz</rs>, <rs type="funder">Satisfai Health</rs>, <rs type="funder">Shire</rs>, <rs type="funder">Sublimity Therapeutics</rs> and <rs type="funder">Takeda</rs>.</s><s xml:id="_E6eX9am">A.B.Q. has received speaking honorarium from <rs type="funder">AbbVie</rs>, <rs type="funder">Apsen</rs> and <rs type="funder">Janssen</rs>.</s><s xml:id="_4ChtfTX">R.A.R.A. has received speaking and consulting honoraria from <rs type="funder">AbbVie</rs>, <rs type="funder">Astra Zeneca</rs>, <rs type="funder">Ferring</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Janssen</rs> and <rs type="funder">Takeda</rs>.</s><s xml:id="_8PPPmfH">D.T.R. has received grant support from <rs type="funder">Takeda</rs>; and has served as a consultant for <rs type="institution">AbbVie</rs>, <rs type="institution">Altrubio</rs>, <rs type="institution">Abivax SA</rs>, <rs type="institution">Altrubio</rs>, <rs type="institution">Avalo Therapeutics</rs>, <rs type="institution">Bausch Health</rs>, <rs type="institution">Bristol-Myers Squibb</rs>, <rs type="institution">Buhlmann Diagnostics</rs>, <rs type="institution">ClostraBio</rs>, <rs type="institution">Connect BioPharma</rs>, <rs type="institution">Douglas Pharmaceuticals</rs>, <rs type="institution">Eli Lilly</rs>, <rs type="institution">Genentech</rs>, <rs type="institution">InDex Pharmaceuticals</rs>, <rs type="institution">Iterative Health</rs>, <rs type="institution">Janssen Pharmaceuticals</rs>, <rs type="institution">Odyssey Therapeutics</rs>, <rs type="institution">Pfizer</rs>, <rs type="institution">Sanofi</rs> and <rs type="institution">Takeda Pharmaceuticals</rs>; he serves on the board of trustees for the <rs type="institution">Crohn's &amp; Colitis Foundation</rs> and is on the board of directors for Cornerstones Health.</s><s xml:id="_qEj9K7F">H.S. has received honoraria for speaking from <rs type="funder">Astellas</rs>, <rs type="funder">AbbVie</rs>, <rs type="funder">Biofermin</rs>, <rs type="funder">EA Pharma</rs>, <rs type="funder">Janssen</rs>, <rs type="funder">Kissei</rs>, <rs type="funder">Miyarisan</rs>, <rs type="funder">Otsuka</rs>, <rs type="person">Tanabe-Mitsubishi</rs>, <rs type="funder">Takeda</rs>, <rs type="person">Tsumura</rs> and <rs type="person">Viatris</rs>; and received grants for research from Toh-so and <rs type="funder">Biofermin</rs>.</s><s xml:id="_pMC4mMN">M.T. has received consulting and speaking fees from <rs type="funder">AbbVie</rs>, <rs type="funder">Janssen</rs> and <rs type="funder">Takeda</rs>.</s><s xml:id="_j8Tfd7E">D.T. received consultation fees, research grants, royalties or honoraria from <rs type="funder">Janssen</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Shaare Zedek Medical Center, Hospital for Sick Children</rs>, <rs type="funder">Ferring</rs>, <rs type="funder">AbbVie</rs>, <rs type="funder">Takeda</rs>, <rs type="funder">Prometheus Biosciences</rs>, <rs type="funder">Lilly</rs>, <rs type="funder">Roche</rs>, <rs type="funder">Thermo Fisher Scientific</rs>, <rs type="funder">BMS</rs> and SorrisoPharma.</s><s xml:id="_jrTbpaa">S.C.W. has received consultancy fees from <rs type="funder">AbbVie</rs>, <rs type="funder">Bristol-Myers Squibb</rs>, <rs type="funder">Celltrion</rs>, <rs type="funder">Ferring Pharmaceuticals</rs>, <rs type="funder">Janssen</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Takeda</rs> and <rs type="person">Tanabe</rs>, and speaker fees from <rs type="funder">AbbVie</rs>, <rs type="funder">Bristol-Myers Squibb</rs>, <rs type="funder">Celltrion</rs>, <rs type="funder">Excelsior Biopharma</rs>, <rs type="funder">Ferring Pharmaceuticals</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Janssen</rs>, <rs type="funder">Sanofi</rs>, Takeda and Tanabe.</s><s xml:id="_5YnGvcH">T.W. received funding for educational activities from AbbVie and Pfizer.</s><s xml:id="_8H7RGfd">J.K.Y.-F. is a speaker bureau member for AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein and Takeda; is a clinical research investigator Bristol Myers Squibb and Takeda; has been member of advisory boards for AbbVie, Celltrion, Ferring, Janssen and Takeda; has received research grants from Takeda; received payments for lectures from AbbVie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein and Takeda; and is an advisory board member of the AbbVie, Celltrion, Ferring, Janssen and Takeda.</s><s xml:id="_Zu96eEP">The other authors declare no competing interests.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_YSyfeeN">
					<idno type="grant-number">G-2108-04777</idno>
				</org>
				<org type="funding" xml:id="_uFWGGWD">
					<idno type="grant-number">PJT-162393</idno>
					<orgName type="grant-name">Scheme Operating Grant</orgName>
				</org>
				<org type="funding" xml:id="_KQ5fNcp">
					<idno type="grant-number">R4030-22</idno>
					<orgName type="program" subtype="full">RGC-RIF</orgName>
				</org>
				<org type="funding" xml:id="_Qftf5u9">
					<idno type="grant-number">NCI202346</idno>
				</org>
				<org type="funding" xml:id="_uxN898m">
					<idno type="grant-number">2017PG-IBD003</idno>
				</org>
				<org type="funding" xml:id="_aEKZMr5">
					<orgName type="program" subtype="full">safety monitoring programs</orgName>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_v84bgEb">Data availability</head><p xml:id="_ZVRrGbD"><s xml:id="_6hX8MxW">The raw data used for systematic review data analysis and input to our models are available at Figshare 87 (<ref type="url" target="https://doi.org/10.6084/m9.figshare.24952557">https://doi.org/10.6084/  m9.figshare.24952557</ref>)</s><s xml:id="_UYYczZ5">and Code Ocean (<ref type="url" target="https://codeocean.com/capsule/8524418/tree/v1">https://codeocean.com/  capsule/8524418/tree/v1</ref>).</s><s xml:id="_canUrQM">Data identified in our systematic review are also available for download or to view and visualize in our interactive data repository (<ref type="url" target="https://kaplan-gi.shinyapps.io/GIVES21/">https://kaplan-gi.shinyapps.io/GIVES21/</ref>).</s><s xml:id="_PZQPafB">The static maps in Fig. <ref type="figure">3</ref> were created in R using the ggplot2 package.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vzzxhgF">Code availability</head><p xml:id="_9DrPwsh"><s xml:id="_p6aCwVH">The code for the systematic review analysis, the machine-learning algorithms and the mathematical modelling, as well as code used to generate figures, is available at Code Ocean (<ref type="url" target="https://codeocean.com/capsule/8524418/tree/v1">https://codeocean.com/  capsule/8524418/tree/v1</ref>).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_DVHEWzX"><p xml:id="_DFzyjge"><s xml:id="_V6ZhJKh">Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_79uuqUU">Reporting summary</head><p xml:id="_8y2Xpas"><s xml:id="_mFhb2SV">Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.</s></p><p xml:id="_ZjmguHY"><s xml:id="_sRtrHw8">Author contributions L.H., J.W.W., S.C.N. and G.G.K. led the study.</s><s xml:id="_c2grKy8">L.H., J.W.W., J.G., M.C., S.C., S.C.N. and G.G.K. conceived and designed the study, conducted analyses, interpreted the results and drafted the manuscript.</s><s xml:id="_SMsJuJ3">L.H. led the machine-learning analyses.</s><s xml:id="_SRRKxkC">M.C. led the PDE model analyses.</s><s xml:id="_QxaDwyZ">J.G. led the societal indicator and ratio analyses.</s><s xml:id="_SmnudJB">J.W.W. led the systematic review.</s><s xml:id="_SgjGvxH">J.W.W., J.G., M.J.B., J.Q., L.C., A.M., S.C.N. and G.G.K. were responsible for primary data acquisition through the systematic review.</s><s xml:id="_GTMRwnj">E.I.B., C.N.B., M.C., R.G., Q.G., R.P. and T.W. interpreted the analysis and critically reviewed the work for important intellectual content.</s><s xml:id="_kvpXBhP">Y.A., M. Abdullah, M.T.A., V.A., R.A.R.A., M. Altuwaijri, D.B., R.B., E.B.-M., J.B., V.H.C., I.D., U.D., S.E.O., A. Forbes, A. Forss, R.G., V.H.D., J.L.H., I.H., P.H., G.-R.J., F.J.-B., J.K., P.K., T.K., P.G.K., P.L.L., C.W.L., J.L., B.L., E.V.L., J.F.L., J.W.Y.M., Y.M., K.K.N., S.O., O.O., M.S.P., A.B.Q., D.T.R., M.S., Y.S., H.S., M.T., D.T., B.I., S.C.W., J.K.Y.-F.</s><s xml:id="_7AVM83C">and S.-K.Y. formed an international group of collaborators who verified data, provided additional data with local expertise and critically reviewed the work.</s><s xml:id="_bE3nwKC">S.C.N. and G.G.K. provided funding for this study.</s><s xml:id="_dxMTTRH">All of the authors edited the manuscript and provided final approval.</s><s xml:id="_3MP7gRh">L.H., J.W.W., S.C.N. and G.G.K. contributed equally to this study.</s><s xml:id="_qxRUeEB">has served as a speaker and consultant for Janssen, Chiesi, Takeda and Kern.</s><s xml:id="_qygu5xj">J.B. reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring and personal fees from Galapagos; outside the submitted work.</s><s xml:id="_3b2n2pS">I.D. received consultation fees/served in advisory boards/speakers' bureaus for AbbVie, Athos, Arena, Celltrion, Celgene/BMS, Eli-Lilly, Ferring, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Janssen, Neopharm, Pfizer, Roche/Genentech, Sangamo, Sublimity, Sandoz, Takeda, Wildbio and Prometheus.</s><s xml:id="_7mcWUEQ">Jill Roberts IBD Center, shareholder: Gutreat, Harp diagnostics.</s><s xml:id="_ypcjzUx">S.E.O. has received honoraria for speaking from AbbVie and Janssen. A. Forss has served as a speaker and advisory board member for Janssen and Tillotts Pharma.</s><s xml:id="_6MhpCgS">R.G. has received research funding from AbbVie, Janssen, Zespri, Comvita, Goodman Fielder and Takeda; he has served on advisory boards for AbbVie, Janssen, Zespri, Comvita and Takeda; and has received honoraria from AbbVie, Janssen, Zespri and Takeda.</s><s xml:id="_GB4RZYV">J.L.H. has received consultation and speaking fee from Janssen, Ferring, AbbVie and Takeda.</s><s xml:id="_Z69mt7N">I.H. has received consulting and speaking honoraria from AbbVie, Janssen, Ferring, LF Asia, Pfizer and Takeda.</s><s xml:id="_Na77txH">B.I. has been member of advisory boards for AbbVie, Janssen and Takeda.</s><s xml:id="_ZfAuXnx">G.-R.J. is funded by a Wellcome Trust Clinical Research Career Development Fellowship and has received speaker fees from AbbVie, Ferring Pharmaceuticals, Janssen, Takeda, Fresenius Kabi and Pfizer.</s><s xml:id="_sFKkVwd">F.J.-B.</s><s xml:id="_x6jRAQR">has received consulting and speaking fees from AbbVie, Janssen, Pfizer, Celltrion and Takeda.</s><s xml:id="_u3etybX">J.K. has served on advisory boards for Janssen Kazakhstan and has been a consultant for Takeda and Ferring; has been on speaker panels for Janssen, Takeda, Ferring, Thermo Fisher Scientific; and has received research funding from Ferring Kazakhstan.</s><s xml:id="_DmZX6u4">G.G.K. has received honoraria for speaking or consultancy from AbbVie, Amgen, Janssen, Pfizer, Sandoz and Pendophram; received grants for research from Ferring and for educational activities from AbbVie, Bristol Myers Squibb, Ferring, Fresenius-Kabi, Janssen, Pfizer, Takeda; he shares ownership of a patent: Treatment of inflammatory disorders, autoimmune disease and PBC; UTI Limited Partnership, assignee; patent WO2019046959A1, PCT/CA2018/051098; 7 September 2018.</s><s xml:id="_y5myhkz">T.K. has served as an advisory board member, consultant or speaker for AbbVie, Activaid, Ajinomoto Bio-Pharma, Alfresa Pharma, Alimentiv, Astellas Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, JMDC, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical.</s><s xml:id="_5TBk68Z">P.G.K. has received consulting and speaking honorarium from AbbVie, Janssen, Pfizer and Takeda.</s><s xml:id="_6ZTE2B4">He also has received scientific grants from Pfizer and Takeda.</s><s xml:id="_YyfCMkf">P.L.L. has been a speaker and/or advisory board member for AbbVie, Amgen, BioJamp, Bristol Myers Squibb, Fresenius Kabi, Genetech, Gilead, Janssen, Merck, Mylan, Organon, Pendopharm, Pfizer, Roche, Sandoz, Takeda, Tillots and Viatris; and has received unrestricted research grants from AbbVie, Gilead, Takeda and Pfizer.</s><s xml:id="_GAHXkEA">C.W.L. is funded by a UK Research and Innovation Future Leaders Fellowship and has acted as a speaker and/or consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_m9wXWfa">Competing interests</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Qsr7qNt">Additional information Supplementary information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KdxRcVT">Statistics</head><p xml:id="_XRm4Y75"><s xml:id="_NyCKmHX">For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HatzKrD">n/a Confirmed</head><p xml:id="_jaWRa2N"><s xml:id="_8xQyPUH">The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly</s></p><p xml:id="_FKdfBNN"><s xml:id="_4dft5Qy">The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FWTmvKZ">A description of all covariates tested</head><p xml:id="_tmjwKPe"><s xml:id="_Z6YkAkW">A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g.</s><s xml:id="_bG8ku4q">means) or other basic estimates (e.g.</s><s xml:id="_kBXd7HP">regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g.</s><s xml:id="_rrFGn5F">confidence intervals) For hypothesis testing, the test statistic (e.g.</s><s xml:id="_UUrsYCJ">F, with confidence effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.</s></p><p xml:id="_gx4kFB4"><s xml:id="_wSMyFGm">For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g.</s><s xml:id="_qtsNv2b">Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dCvB4t9">Software and code</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7ZqJUWR">Policy information about availability of computer code</head><p xml:id="_QcCx375"><s xml:id="_WBp5qmE">Data collection Data extraction from published graphs was conducted using OriginPro2018 (v.</s><s xml:id="_VnVXf9U">b9.5.5.409) or juicer (v. 0</s><s xml:id="_d4t5JxC">.1).</s><s xml:id="_5MeZh2q">No additional software was used for data collection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8qtNqF3">Data analysis</head><p xml:id="_QyHzTdk"><s xml:id="_5yzhFxC">Statistical analyses and machine learning were performed in R (v.4.2.2) and included packages randomForest (v.</s><s xml:id="_EXeEHKW">4.7-1.1)</s><s xml:id="_StkGmcz">and emmeans (v.</s><s xml:id="_uCewzsV">1.10.3).</s><s xml:id="_DVTDht8">Mathematical modelling was performed in Mathematica (v.13.1).</s><s xml:id="_qrdjZyv">Maps in Figure <ref type="figure">3</ref> were created with ggplot2 (v.</s><s xml:id="_3KDb4ED">3.5.1).</s></p><p xml:id="_QMwa5wG"><s xml:id="_Px3XH34">For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers.</s><s xml:id="_HzFe4PT">We encourage code deposition in a community repository (e.g.</s><s xml:id="_MS8xCRb">GitHub).</s><s xml:id="_G2fubhq">See the Nature Portfolio guidelines for submitting code &amp; software for further information.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RMARBUb">Data Policy information about availability of data</head><p xml:id="_YQ6bCh6"><s xml:id="_P4ypqS2">All manuscripts must include a data availability statement.</s><s xml:id="_acrvkSg">This statement should provide the following information, where applicable:</s></p><p xml:id="_bz62P6R"><s xml:id="_SV2VbCe">-Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy</s></p><p xml:id="_e92PTVR"><s xml:id="_7W7yFfU">The raw data used for systematic review data analysis and input to our models are available at <ref type="url" target="https://doi.org/10.6084/m9.figshare.24952557">https://doi.org/10.6084/m9.figshare.24952557</ref></s><s xml:id="_zXRkzNw">and in the Code Ocean capsule linked to this manuscript.</s><s xml:id="_tePSXva">Data identified in our systematic review are also available for download or to view and visualize in our interactive data nature portfolio | reporting summary</s></p><p xml:id="_C2r6nBt"><s xml:id="_vhjHUDQ">April 2023 repository at <ref type="url" target="https://kaplan-gi.shinyapps.io/GIVES21/">https://kaplan-gi.shinyapps.io/GIVES21/</ref>.</s></p><p xml:id="_nKGMuVQ"><s xml:id="_n3MVcee">The systematic review was performed through Medline (<ref type="url" target="https://www.nlm.nih.gov/medline/medline_overview.html">https://www.nlm.nih.gov/medline/medline_overview.html</ref>),</s><s xml:id="_ta7zx8s">Embase (<ref type="url" target="https://www.elsevier.com/products/">https://www.elsevier.com/products/</ref></s><s xml:id="_x3aTEX5">embase), PubMed (<ref type="url" target="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</ref>), and Web of Science (<ref type="url" target="https://clarivate.com/academia-government/scientific-and-academic-research/">https://clarivate.com/academia-government/scientific-and-academic-research/</ref></s><s xml:id="_j54AUKm">research-discovery-and-referencing/web-of-science/).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_94sAcNf">Research involving human participants, their data, or biological material</head><p xml:id="_pw56cTP"><s xml:id="_wmfqhHf">Policy information about studies with human participants or human data.</s><s xml:id="_mQBDjZ3">See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RCb9g3S">Reporting on sex and gender</head><p xml:id="_EnVqBfq"><s xml:id="_wBq2zPb">Sex-and gender-based analyses were not performed.</s><s xml:id="_zFcVKzA">Although sex and gender differences can be observed in the epidemiology of inflammatory bowel disease, the systematic review data gathered and subsequently analyzed were not stratified by sex or gender.</s></p><p xml:id="_8bJgyEG"><s xml:id="_vQNrRxM">Reporting on race, ethnicity, or other socially relevant groupings</s></p><p xml:id="_8e7Zw5R"><s xml:id="_v8BFHS9">Analyses based on race and ethnicity were not performed.</s><s xml:id="_PVVdms8">The systematic review data gathered and subsequently analyzed corresponded to global geography, but stratifications by race, ethnicity, or other socially relevant groupings were not collected as non-general populations was an exclusion criteria.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_m3QhMqA">Population characteristics</head><p xml:id="_Uwm9cSx"><s xml:id="_pwV9MUG">Global populations: all ages, genders, and races.</s></p><p xml:id="_9jcVu5b"><s xml:id="_WsrV2VY">Recruitment</s></p><p xml:id="_jxjG7Aj"><s xml:id="_VKxhvm7">Note that full information on the approval of the study protocol must also be provided in the manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_T9n62qd">Field-specific reporting</head><p xml:id="_EmaJURV"><s xml:id="_w2qnbtG">Please select the one below that is the best fit for your research.</s><s xml:id="_Ke3CsnC">If you are not sure, read the appropriate sections before making your selection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_5M37UQE">Life sciences Behavioural &amp; social sciences Ecological, evolutionary &amp; environmental sciences</head><p xml:id="_Vg2b323"><s xml:id="_MtemUPw">For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Tvfq7jj">Life sciences study design</head><p xml:id="_DZnu3un"><s xml:id="_an4cMxY">All studies must disclose on these points even when the disclosure is negative.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_pw37xmX">Sample size</head><p xml:id="_gJte3Fm"><s xml:id="_vUHqzHg">A total of 522 population-based studies reporting on the incidence and prevalence of inflammatory bowel disease were include in our analyses.</s><s xml:id="_uy5bH75">Machine learning analyses were performed on a total of 5,521 data points (Crohn's disease incidence n = 2,070; ulcerative colitis incidence n = 1,884; Crohn's disease prevalence n = 776; ulcerative colitis prevalence = 791).</s><s xml:id="_KPyQYnv">Incidence and prevalence data for Crohn's disease and ulcerative colitis across each global region for each year of data were merged to create a total of 2,489 random forest classifications.</s><s xml:id="_473hytY">Mathematical modelling of age-stratified incidence and prevalence data from 3 regions, i.e., Canada, Denmark, and Scotland, was completed (Supplementary Table <ref type="table">7</ref>).</s></p><p xml:id="_kQmZwfN"><s xml:id="_YhWjb5S">Data exclusions Our exclusion criteria were as follows: No defined geographic region, less than one year of data, study population is pediatric only (i.e., did not include adult and/or senior populations), self-reported cases identified by survey, reviews, and clinical trials.</s><s xml:id="_3CgZYDZ">Exclusion criteria were preestablished at the outset of the systematic review and align with previous systematic reviews that the current work builds on.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YYQj8Ny">Replication</head><p xml:id="_WAz8Ke8"><s xml:id="_3rbPagK">We identified and reassessed population-based studies included in two previous systematic reviews on the incidence and prevalence of inflammatory bowel disease.</s><s xml:id="_d7Q22te">Our systematic review was conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA 2020).</s><s xml:id="_Cg2uJSc">Data and code are made available for reproducibility.</s></p><p xml:id="_5dYqH8h"><s xml:id="_Rcb3xAM">Randomization Training and validation data were randomly sampled.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7dR9FCt">Blinding</head><p xml:id="_nMHGNGh"><s xml:id="_4kz3hPc">A validation set was withheld at model fitting.</s><s xml:id="_xY4vjng">All test data (approximately 35% of our dataset) were unseen by the model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cQDY3dn">Reporting for specific materials, systems and methods</head><p xml:id="_gyMVTsg"><s xml:id="_WZR8qUC">We require information from authors about some types of materials, experimental systems and methods used in many studies.</s><s xml:id="_AXwYz4r">Here, indicate whether each material, system or method listed is relevant to your study.</s><s xml:id="_4SHZky5">If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_HaGmBDN">The global burden of IBD: from 2015 to 2025</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrgastro.2015.150</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6SXvS2P">Nat. Rev. Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="720" to="727" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720-727 (2015).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_qWqvRUp">The four epidemiological stages in the global evolution of inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Windsor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZcxXU4W">Nat. Rev. Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="56" to="66" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan, G. G. &amp; Windsor, J. W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18, 56-66 (2021).</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_y44bhp9">Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Molodecky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7ZXuCd9">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="46" to="54" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54 (2012).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_fttkJZy">Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Ng</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(17)32448-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aNsrQ3t">Lancet</title>
		<imprint>
			<biblScope unit="volume">390</biblScope>
			<biblScope unit="page" from="2769" to="2778" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769-2778 (2017).</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_s5rgJ49">Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Ng</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-1253(16)30077-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fn4CVDd">Lancet Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="307" to="316" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan, G. G. &amp; Ng, S. C. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol. Hepatol. 1, 307-316 (2016).</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_njCATfY">Environmental factors associated with risk of Crohn&apos;s disease development in the Crohn&apos;s and Colitis Canada-Genetic, Environmental, Microbial Project</title>
		<author>
			<persName><forename type="first">M</forename><surname>Xue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dC36bWh">Clin. Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1889" to="1897" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Xue, M. et al. Environmental factors associated with risk of Crohn&apos;s disease development in the Crohn&apos;s and Colitis Canada-Genetic, Environmental, Microbial Project. Clin. Gastroenterol. Hepatol. 22, 1889-1897 (2024).</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_Y8NgcNd">Understanding and preventing the global increase of inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Ng</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2016.10.020</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rP2Jyu7">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="313" to="321" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaplan, G. G. &amp; Ng, S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152, 313-321 (2017).</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_yfV9K8W">Twenty-first century trends in the global epidemiology of pediatriconset inflammatory bowel disease: systematic review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kuenzig</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2021.12.282</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gFRByXC">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="1147" to="1159" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kuenzig, M. E. et al. Twenty-first century trends in the global epidemiology of pediatric- onset inflammatory bowel disease: systematic review. Gastroenterology 162, 1147-1159 (2022).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_VSYf79H">A tale of two diseases: the history of inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mulder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Noble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Justinich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Duffin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zpYgbUm">J. Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="341" to="348" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mulder, D. J., Noble, A. J., Justinich, C. J. &amp; Duffin, J. M. A tale of two diseases: the history of inflammatory bowel disease. J. Crohns Colitis 8, 341-348 (2014).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_A4RqfMP">The incidence of Crohn&apos;s disease in Cardiff over the last 75 years: an update for 1996-2005</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gunesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Hawthorne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DSBscux">Aliment Pharmacol. Ther</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="211" to="219" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gunesh, S., Thomas, G. A., Williams, G. T., Roberts, A. &amp; Hawthorne, A. B. The incidence of Crohn&apos;s disease in Cardiff over the last 75 years: an update for 1996-2005. Aliment Pharmacol. Ther. 27, 211-219 (2008).</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_PAqWEPN">Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Vegh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e6Zxutr">J. Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1506" to="1515" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vegh, Z. et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J. Crohns Colitis 8, 1506-1515 (2014).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_UhKJHwA">Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lewis</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2023.07.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_t3pq3Jm">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="1197" to="1205" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewis, J. D. et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology 165, 1197-1205 (2023).</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_gANgNhk">IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Jones</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2019-318936</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZMUXCkR">Gut</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1953" to="1960" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jones, G. R. et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut 68, 1953-1960 (2019).</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_3JVwWp7">Past and future burden of inflammatory bowel diseases based on modeling of population-based data</title>
		<author>
			<persName><forename type="first">S</forename><surname>Coward</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2019.01.002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uA9qRAU">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="1345" to="1353" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Coward, S. et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156, 1345-1353 (2019).</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_MSWRE8h">Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Coward</surname></persName>
		</author>
		<idno type="DOI">10.14309/ajg.0000000000002687</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3cThXG6">Am. J. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1563" to="1570" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Coward, S. et al. Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis. Am. J. Gastroenterol. 119, 1563-1570 (2024).</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_9FqCSAW">Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Quaresma</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.lana.2022.100298</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UhYGAgt">Lancet Reg. Health Am</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">100298</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Quaresma, A. B. et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg. Health Am. 13, 100298 (2022).</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_5Qk5dgj">Top 10 algorithms in data mining</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HxUrBcE">Knowl. Inform. Syst</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1" to="37" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wu, X. et al. Top 10 algorithms in data mining. Knowl. Inform. Syst. 14, 1-37 (2008).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_yzAx3kB">Random forests</title>
		<author>
			<persName><forename type="first">L</forename><surname>Breiman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qJpJzJJ">Mach. Learn</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="5" to="32" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Breiman, L. Random forests. Mach. Learn. 45, 5-32 (2001).</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_Js9Zs3e">The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology &amp; Hepatology Commission</title>
		<author>
			<persName><forename type="first">J</forename><surname>Burisch</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-1253(23)00003-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_g7hWrH8">Lancet Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="458" to="492" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burisch, J. et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology &amp; Hepatology Commission. Lancet Gastroenterol. Hepatol. 8, 458-492 (2023).</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_Dg45XJB">Augmented human development in the age of globalization</title>
		<author>
			<persName><forename type="first">Prados</forename><surname>De La Escosura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cpumxQ7">Econ. Hist. Rev</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="946" to="975" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Prados de la Escosura, L. Augmented human development in the age of globalization. Econ. Hist. Rev. 74, 946-975 (2021).</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<ptr target="apps.who.int/gho/data/node.main.A900A?lang=en" />
		<title level="m" xml:id="_E54dt2F">Prevalence of Obesity Among Adults, BMI≥30, Age-Standardized Estimates by Country</title>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2017">2017</date>
		</imprint>
		<respStmt>
			<orgName>Global Health Observatory</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Global Health Observatory. Prevalence of Obesity Among Adults, BMI≥30, Age-Standardized Estimates by Country (World Health Organization, 2017); apps.who.int/gho/data/node. main.A900A?lang=en.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<idno type="DOI">10.18356/cd4eece8-en</idno>
		<ptr target=".un.org/wup/Download/" />
		<title level="m" xml:id="_t9AGmhx">World Urbanization Prospects: The 2018 Revision</title>
		<imprint>
			<publisher>United Nations</publisher>
			<date type="published" when="2018">2018</date>
			<biblScope unit="page">population</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Department of Economic and Social Affairs-Population Division. World Urbanization Prospects: The 2018 Revision (United Nations, 2018); population.un.org/wup/Download/.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" xml:id="_XzAwuFx">Tracking Universal Health Coverage: 2023 Global Monitoring Report</title>
		<imprint>
			<publisher>World Health Organization and International Bank for Reconstruction and Development/The World Bank</publisher>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tracking Universal Health Coverage: 2023 Global Monitoring Report (World Health Organization and International Bank for Reconstruction and Development/The World Bank, 2023).</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_G8wuSRP">Is the world converging to a &apos;Western diet&apos;?</title>
		<author>
			<persName><forename type="first">A</forename><surname>Azzam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8GSd6Ze">Publ. Health Nutr</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="309" to="317" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Azzam, A. Is the world converging to a &apos;Western diet&apos;? Publ. Health Nutr. 24, 309-317 (2021).</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_fgXjnqr">Age-and time-dependent model of the prevalence of noncommunicable diseases and application to dementia in Germany</title>
		<author>
			<persName><forename type="first">R</forename><surname>Brinks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Landwehr</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tpb.2013.11.006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qxvzCXH">Theor. Popul. Biol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brinks, R. &amp; Landwehr, S. Age-and time-dependent model of the prevalence of non- communicable diseases and application to dementia in Germany. Theor. Popul. Biol. 92, 62-68 (2014). 26</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main" xml:id="_G28nDKe">Projected Population, by Projection Scenario, Age and Sex, as of July 1</title>
		<idno type="DOI">10.1787/data-00212-en</idno>
		<ptr target="www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710005701" />
		<imprint>
			<date type="published" when="2022">2022</date>
			<publisher>Statistics Canada</publisher>
		</imprint>
	</monogr>
	<note>(x 1,000</note>
	<note type="raw_reference">Projected Population, by Projection Scenario, Age and Sex, as of July 1 (x 1,000) (Statistics Canada, 2022); www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid= 1710005701.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<ptr target="extranet.dst.dk/pyramide/pyramide.htm#!&amp;l=en" />
		<title level="m" xml:id="_carCJqx">Population Projection (FRDK</title>
		<meeting><address><addrLine>Statbank Denmark</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2023">2023</date>
			<biblScope unit="volume">123</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Population Projection (FRDK123) (Statbank Denmark, 2023); extranet.dst.dk/pyramide/ pyramide.htm#!&amp;l=en.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<ptr target="www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/population/population-projections/sub-national-population-projections/2018-based/detailed-datasets" />
		<title level="m" xml:id="_SmMxc64">2018-Based Principal Population Projections For 2018-2043, By Sex, NHS Board Area and Single Year of Age</title>
		<imprint>
			<publisher>National Records of Scotland</publisher>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">2018-Based Principal Population Projections For 2018-2043, By Sex, NHS Board Area and Single Year of Age (National Records of Scotland, 2020); www.nrscotland.gov.uk/ statistics-and-data/statistics/statistics-by-theme/population/population-projections/ sub-national-population-projections/2018-based/detailed-datasets.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<author>
			<persName><forename type="first">W</forename><surname>Cheney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kincaid</surname></persName>
		</author>
		<title level="m" xml:id="_3raRdrj">Numerical Mathematics and Computing 5th edn</title>
		<imprint>
			<publisher>Brooks/ Cole-Thompson</publisher>
			<date type="published" when="2004">2004</date>
			<biblScope unit="page">633</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Cheney, W. &amp; Kincaid, D. Numerical Mathematics and Computing 5th edn, 633 (Brooks/ Cole-Thompson, 2004).</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_j8P539c">Lifestyle factors for the prevention of inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Lopes</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2022-328174</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VpxHkW3">Gut</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1093" to="1100" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lopes, E. W. et al. Lifestyle factors for the prevention of inflammatory bowel disease. Gut 72, 1093-1100 (2023).</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_GDqA7n6">The cost of IBD care-how to make it sustainable</title>
		<author>
			<persName><forename type="first">J</forename><surname>Burisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Claytor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2024.06.049</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_682VvT3">Clin. Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="386" to="395" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burisch, J., Claytor, J., Hernandez, I., Hou, J. K. &amp; Kaplan, G. G. The cost of IBD care-how to make it sustainable. Clin. Gastroenterol. Hepatol. 23, 386-395 (2024).</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_fJ3nnyN">Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Ananthakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Ng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2020.01.028</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tvWJYnb">Clin. Gastroenterol. Hepatol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1252" to="1260" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ananthakrishnan, A. N., Kaplan, G. G. &amp; Ng, S. C. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin. Gastroenterol. Hepatol. 18, 1252-1260 (2020).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_KtyhKcT">Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21(st) century (GIVES-21)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W Y</forename><surname>Mak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7WGngd3">BMC Med. Res. Methodol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">129</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mak, J. W. Y. et al. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21(st) century (GIVES-21). BMC Med. Res. Methodol. 23, 129 (2023).</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_sQuEzXU">Estimated prevalence of ulcerative colitis and Crohn&apos;s disease in Japan in 2014: an analysis of a nationwide survey</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Murakami</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00535-019-01603-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YsQUtX3">J. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1070" to="1077" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Murakami, Y. et al. Estimated prevalence of ulcerative colitis and Crohn&apos;s disease in Japan in 2014: an analysis of a nationwide survey. J. Gastroenterol. 54, 1070-1077 (2019).</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_zJhZNwe">A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_b5WfNFn">J. Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1410" to="1417" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Park, S. H. et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J. Crohns Colitis 13, 1410-1417 (2019).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_27hJpeB">Trend and geographic variation in incidence and prevalence of inflammatory bowel disease in regions across China: a nationwide employee study between 2013 and 2016</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Qian</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmed.2022.900251</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cckcvVG">Front. Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">900251</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yang, H., Zhou, R., Bai, X., Guo, M., Ruan, G., Wang, L. &amp; Qian, J. Trend and geographic variation in incidence and prevalence of inflammatory bowel disease in regions across China: a nationwide employee study between 2013 and 2016. Front. Med. 9, 900251 (2022).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_WHbEc6W">A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Mokhtar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v6zXTHh">BMC Publ. Health</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">550</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mokhtar, N. M. et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Publ. Health 19, 550 (2019).</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_suVRbdA">Sex-based differences in the incidence of inflammatory bowel diseasespooled analysis of population-based studies from the Asia-Pacific region</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Shah</surname></persName>
		</author>
		<idno type="DOI">10.1111/apt.15178</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dtYdN4F">Aliment Pharmacol. Ther</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="904" to="911" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shah, S. C. et al. Sex-based differences in the incidence of inflammatory bowel diseases- pooled analysis of population-based studies from the Asia-Pacific region. Aliment Pharmacol. Ther. 49, 904-911 (2019).</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_RBd8Dwv">The 2023 impact of inflammatory bowel disease in Canada: indirect (individual and societal) and direct out-of-pocket costs</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kuenzig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_y4wUQGe">J. Can. Assoc. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="16" to="S22" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kuenzig, M. E. et al. The 2023 impact of inflammatory bowel disease in Canada: indirect (individual and societal) and direct out-of-pocket costs. J. Can. Assoc. Gastroenterol. 6, S16-S22 (2023).</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_Uaxvjya">Commentary on the epidemiology of inflammatory bowel disease in compounding prevalence nations: toward sustaining healthcare delivery</title>
		<author>
			<persName><forename type="first">M</forename><surname>Herauf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BzSsBQg">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="949" to="956" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herauf, M. et al. Commentary on the epidemiology of inflammatory bowel disease in compounding prevalence nations: toward sustaining healthcare delivery. Gastroenterology 166, 949-956 (2024).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_5d5nFv3">Challenges in designing a national surveillance program for inflammatory bowel disease in the United States</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Long</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JBqNVEt">Inflamm. Bowel Dis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="398" to="415" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Long, M. D. et al. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm. Bowel Dis. 20, 398-415 (2014).</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_HyGjqe8">Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Molodecky</surname></persName>
		</author>
		<idno type="DOI">10.1002/ibd.21511</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vmFqpHK">Inflamm. Bowel Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1792" to="1799" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Molodecky, N. A. et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 1792-1799 (2011).</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_uVVwMe3">The 2023 impact of inflammatory bowel disease in Canada: special populations-IBD in seniors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Shaffer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j6VaVBK">J. Can. Assoc. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="45" to="S54" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shaffer, S. R. et al. The 2023 impact of inflammatory bowel disease in Canada: special populations-IBD in seniors. J. Can. Assoc. Gastroenterol. 6, S45-S54 (2023).</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_DvJJp7f">The 2023 impact of inflammatory bowel disease in Canada: access to and models of care</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mathias</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4KmPcrB">J. Can. Assoc. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="111" to="S121" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mathias, H. et al. The 2023 impact of inflammatory bowel disease in Canada: access to and models of care. J. Can. Assoc. Gastroenterol. 6, S111-S121 (2023).</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_BNyKR2c">Environmental risk factors of inflammatory bowel disease: towards a strategy of preventative health</title>
		<author>
			<persName><forename type="first">T</forename><surname>Chhibba</surname></persName>
		</author>
		<idno type="DOI">10.1093/ecco-jcc/jjaf042</idno>
		<ptr target="https://doi.org/10.1093/ecco-jcc/jjaf042" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_7SHqJAc">J. Crohns Colitis</title>
		<imprint>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chhibba, T. et al. Environmental risk factors of inflammatory bowel disease: towards a strategy of preventative health. J. Crohns Colitis https://doi.org/10.1093/ecco-jcc/jjaf042 (2025).</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_G3B9cbP">Gut microbiome composition is associated with future onset of Crohn&apos;s disease in healthy first-degree relatives</title>
		<author>
			<persName><forename type="first">Raygoza</forename><surname>Garay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yCVNTJc">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="670" to="681" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raygoza Garay, J. A. et al. Gut microbiome composition is associated with future onset of Crohn&apos;s disease in healthy first-degree relatives. Gastroenterology 165, 670-681 (2023).</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_TyHvSNQ">Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Torres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hXnYV5G">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="96" to="104" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Torres, J. et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology 159, 96-104 (2020).</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_EM2zmgy">Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Livanos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VbtQU9G">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="619" to="629" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Livanos, A. E. et al. Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164, 619-629 (2023).</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_uED2YfE">An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Herold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4jW3XdH">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="page" from="603" to="613" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603-613 (2019).</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_ZsqbJSF">Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Cope</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d9mJXNM">Marcellus Simadibrata</title>
		<imprint>
			<biblScope unit="volume">403</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2024-10-06">2024. 10. 6,11. 24. 25. 27. Sun 51,52</date>
			<publisher>Research Group Lindsay Hracs</publisher>
			<pubPlace>Joseph W. Windsor</pubPlace>
		</imprint>
	</monogr>
	<note>Article Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21 Fabián Juliao Lancet Charlie W. Lees Jamilya Kaibullayeva Siew C Gilaad G. Kaplan</note>
	<note type="raw_reference">Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838-849 (2024). Article Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group Lindsay Hracs 1,70 , Joseph W. Windsor 1,70 , Stephanie Coward 1 , Yvonne Abbey 3 , Murdani Abdullah 4 , Maria T. Abreu 5,6 , Vineet Ahuja 6,7 , Raja Affendi Raja Ali 8 , Mansour Altuwaijri 9 , Domingo Balderramo 10 , Rupa Banerjee 6,11 , Eric I. Benchimol 12,13,14,15 , Charles N. Bernstein 6,16 , Eduard Brunet-Mas 17,18,19 , Johan Burisch 6,20,21,22 , Vui Heng Chong 23 , Iris Dotan 6,24 , Usha Dutta 25 , Sara El Ouali 26,27 , Angela Forbes 28 , Anders Forss 29 , Richard Gearry 6,28 , Viet Hang Dao 30 , Juanda Leo Hartono 31,32 , Ida Hilmi 33 , Phoebe Hodges 34,35 , Gareth-Rhys Jones 36 , Fabián Juliao-Baños 37 , Jamilya Kaibullayeva 38,39 , Paul Kelly 34,35 , Taku Kobayashi 40,41 , Paulo Gustavo Kotze 6,42 , Peter L. Lakatos 6,43,44 , Charlie W. Lees 45,46 , Julajak Limsrivilai 47 , Bobby Lo 20,21 , Edward V. Loftus Jr 6,48 , Jonas F. Ludvigsson 29,49 , Joyce W. Y. Mak 50 , YingLei Miao 51,52 , Ka Kei Ng 53 , Shinji Okabayashi 54 , Ola Olén 55 , Remo Panaccione 1,6 , Mukesh Sharma Paudel 56 , Abel Botelho Quaresma 57,58 , David T. Rubin 6,59 , Marcellus Simadibrata 4 , Yang Sun 51,52 , Hidekazu Suzuki 60 , Martin Toro 61 , Dan Turner 6,62 , Beatriz Iade 63 , Shu Chen Wei 64 , Jesus K. Yamamoto-Furusho 65 , Suk-Kyun Yang 66 , Siew C. Ng 6,67,68,69,71 &amp; Gilaad G. Kaplan 1,6,71</note>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<author>
			<persName><forename type="first">F</forename><surname>Widjaja</surname></persName>
		</author>
		<title level="m" xml:id="_twuDyWC">6 International Organization for the study of Inflammatory Bowel Disease (IOIBD)</title>
		<meeting><address><addrLine>Los Angeles, CA, USA; Stockholm, Sweden; New Delhi, India</addrLine></address></meeting>
		<imprint>
			<biblScope unit="volume">7</biblScope>
		</imprint>
		<respStmt>
			<orgName>Cedars-Sinai Medical Center ; Department of Gastroenterology, All India Institute of Medical Sciences</orgName>
		</respStmt>
	</monogr>
	<note>Inflammatory Bowel Disease Institute</note>
	<note type="raw_reference">F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6 International Organization for the study of Inflammatory Bowel Disease (IOIBD), Stockholm, Sweden. 7 Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Sir</forename><surname>Jeffrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cheah</forename><surname>Sunway</surname></persName>
		</author>
		<idno type="DOI">10.21474/ijar01/2917</idno>
		<imprint>
			<biblScope unit="page">10</biblScope>
			<pubPlace>Riyadh, Saudi Arabia</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Medical School, Faculty of Medical and Life Sciences, Sunway University, Selangor, Malaysia. 9 Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Selangor, Malaysia. 9 Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. 10</note>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title/>
		<author>
			<orgName type="collaboration">IBD Center</orgName>
		</author>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">14</biblScope>
			<pubPlace>Hyderabad, India; Toronto, Ontario, Canada; Toronto, Ontario, Canada</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Asian Institute of Gastroenterology ; SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids) ; Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">IBD Center, Asian Institute of Gastroenterology, Hyderabad, India. 12 SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada. 13 Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 14</note>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<author>
			<persName><surname>Ciberehd</surname></persName>
		</author>
		<idno type="DOI">10.5171/2014.117728</idno>
		<title level="m" xml:id="_nRrAaA3">Instituto de Salud Carlos III</title>
		<meeting><address><addrLine>Madrid, Spain; Barcelona, Spain</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1920">19. 20</date>
		</imprint>
		<respStmt>
			<orgName>Departament de Medicina, Universitat Autònoma de Barcelona</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. 19 Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. 20</note>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<idno type="DOI">10.15420/ecr.2016:33:2</idno>
		<title level="m" xml:id="_vBj8Z4T">21 Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults</title>
		<meeting><address><addrLine>Hvidovre, Denmark; Hvidovre, Denmark; Copenhagen, Denmark; Brunei Darussalam</addrLine></address></meeting>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">24</biblScope>
		</imprint>
		<respStmt>
			<orgName>Gastrounit, Medical Division, Copenhagen University Hospital-Amager and Hvidovre ; Copenhagen University Hospital-Amager and Hvidovre ; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen ; Division of Gastroenterology and Hepatology, Department of Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Bandar Seri Begawan</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Gastrounit, Medical Division, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark. 21 Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark. 22 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 23 Division of Gastroenterology and Hepatology, Department of Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Bandar Seri Begawan, Brunei Darussalam. 24</note>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Yong</forename><surname>Loo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lin</forename><surname>School</surname></persName>
		</author>
		<author>
			<persName><surname>Medicine</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">32</biblScope>
			<pubPlace>Singapore, Singapore</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National University of Singapore</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 32</note>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Januário</forename><surname>Conde</surname></persName>
		</author>
		<author>
			<persName><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sar</forename><surname>Macao</surname></persName>
		</author>
		<imprint>
			<date>57</date>
			<biblScope unit="volume">54</biblScope>
			<pubPlace>China; Kyoto, Japan; Stockholm, Sweden; Kathmandu, Nepal; Joaçaba, Brazil; Curitiba, Brazil; Chicago, IL, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University ; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet ; Department of Gastroenterology, National Academy of Medical Sciences ; Universidade do Oeste de Santa Catarina ; Health Sciences Postgraduate Program, Pontifícia Universidade Católica do Paraná ; Bowel Disease Center, University of Chicago Medicine</orgName>
		</respStmt>
	</monogr>
	<note>UNOESC Curso de Medicina Inflammatory</note>
	<note type="raw_reference">Conde S. Januário Hospital, Macao SAR, China. 54 Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan. 55 Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 56 Department of Gastroenterology, National Academy of Medical Sciences, Kathmandu, Nepal. 57 UNOESC Curso de Medicina: Universidade do Oeste de Santa Catarina, Joaçaba, Brazil. 58 Health Sciences Postgraduate Program, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil. 59 Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title/>
		<author>
			<orgName type="collaboration">The Juliet Keidan Institute of Pediatric Gastroenterology &amp; Nutrition</orgName>
		</author>
		<idno type="DOI">10.25005/2074-0581-2023-25-3-441-447</idno>
		<imprint>
			<pubPlace>Jerusalem, Israel</pubPlace>
		</imprint>
		<respStmt>
			<orgName>The Hebrew University of Jerusalem ; Shaare Zedek Medical Center</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">The Juliet Keidan Institute of Pediatric Gastroenterology &amp; Nutrition, The Hebrew University of Jerusalem, Shaare Zedek Medical Center, Jerusalem, Israel.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title/>
		<author>
			<orgName type="collaboration">Inflammatory Bowel Disease Clinic</orgName>
		</author>
		<imprint>
			<biblScope unit="page">66</biblScope>
			<pubPlace>Mexico City, Mexico</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Department of Gastroenterology ; National Institute of Medical Sciences and Nutrition and National Autonomous University of Mexico (UNAM)</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Inflammatory Bowel Disease Clinic, Department of Gastroenterology, National Institute of Medical Sciences and Nutrition and National Autonomous University of Mexico (UNAM), Mexico City, Mexico. 66</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_ggdD2fD">The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tGmzpmt">Brit. Med. J</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Brit. Med. J. 372, n71 (2021).</note>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
		<idno type="DOI">10.32614/cran.package.maddison</idno>
		<ptr target="www.rug.nl/ggdc/historicaldevelopment/maddison/releases/maddison-project-database-2020?lang=en" />
		<title level="m" xml:id="_dm8dR4w">Maddison Style Estimates of the Evolution of the World Economy: A New 2020 Update</title>
		<imprint>
			<publisher>Maddison Project Database</publisher>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Maddison Style Estimates of the Evolution of the World Economy: A New 2020 Update (Maddison Project Database, 2020); www.rug.nl/ggdc/historicaldevelopment/maddison/ releases/maddison-project-database-2020?lang=en.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<ptr target="www.ons.gov.uk/datasets/mid-year-pop-est/editions/mid-2020-april-2021-geography/versions/1" />
		<title level="m" xml:id="_AH7N4VY">mid-2020-april-2021-geography</title>
		<meeting><address><addrLine>England and Wales, Scotland and Northern Ireland</addrLine></address></meeting>
		<imprint>
			<publisher>Office for National Statistics</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>Population estimates for UK</note>
	<note type="raw_reference">Population estimates for UK, England and Wales, Scotland and Northern Ireland: mid- 2020-april-2021-geography (Office for National Statistics, 2022); www.ons.gov.uk/ datasets/mid-year-pop-est/editions/mid-2020-april-2021-geography/versions/1.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<monogr>
		<ptr target="www.statbank.dk/statbank5a/selectvarval/define.asp?PLanguage=1&amp;subword=tabsel&amp;MainTable=FOLK1A&amp;PXSId=199113&amp;tablestyle=&amp;ST=SD&amp;buttons=0" />
		<title level="m" xml:id="_hYVG6Pz">FOLK1A: Population at the First Day of the Quarter by Region, Sex, Age and Marital Status</title>
		<imprint>
			<publisher>Statistics Denmark</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">FOLK1A: Population at the First Day of the Quarter by Region, Sex, Age and Marital Status (Statistics Denmark, 2022); www.statbank.dk/statbank5a/selectvarval/define.asp?PLangu age=1&amp;subword=tabsel&amp;MainTable=FOLK1A&amp;PXSId=199113&amp;tablestyle=&amp;ST=SD&amp;butto ns=0.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<monogr>
		<ptr target="www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101A/BefolkningNy/" />
		<title level="m" xml:id="_9JA8nzT">Population by Region, Marital Status, Age and Sex: Year 1968-2021</title>
		<meeting><address><addrLine>Statistics Sweden</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Population by Region, Marital Status, Age and Sex: Year 1968-2021 (Statistics Sweden, 2022); www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101A/ BefolkningNy/.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<ptr target=".un.org/dataportal/home" />
		<title level="m" xml:id="_M37qPGD">World Population Prospects 2019: Data Portal</title>
		<imprint>
			<publisher>United Nations Department of Economic and Social Affairs-Population Division</publisher>
			<date type="published" when="2019">2019</date>
			<biblScope unit="page">population</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">World Population Prospects 2019: Data Portal (United Nations Department of Economic and Social Affairs-Population Division, 2019); population.un.org/dataportal/home.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<monogr>
		<ptr target="www2.census.gov/programs-surveys/popest/tables/" />
		<title level="m" xml:id="_AHQBwAs">Estimates of Resident Population Change and Rankings for Counties in Minnesota</title>
		<imprint>
			<publisher>United States Census Bureau</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Estimates of Resident Population Change and Rankings for Counties in Minnesota (United States Census Bureau, 2022); www2.census.gov/programs-surveys/popest/tables/.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<monogr>
		<ptr target="www2.census.gov/library/publications/decennial/1950/population-volume-1/vol-01-26.pdf" />
		<title level="m" xml:id="_wB86RSM">Number of Inhabitants</title>
		<imprint>
			<publisher>Minnesota (United States Census Bureau</publisher>
			<date type="published" when="1952">1952</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Number of Inhabitants: Minnesota (United States Census Bureau, 1952); www2.census. gov/library/publications/decennial/1950/population-volume-1/vol-01-26.pdf.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_UFDPRq4">Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Munn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lisy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Riitano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tufanaru</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9VWYfks">Int. J. Evid. Based Healthc</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="147" to="153" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Munn, Z., Moola, S., Lisy, K., Riitano, D. &amp; Tufanaru, C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int. J. Evid. Based Healthc. 13, 147-153 (2015).</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s7eHc2C">OriginPro</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">409</biblScope>
			<date type="published" when="2018">2018</date>
			<publisher>OriginLab</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">OriginPro v.b9.5.5.409 (OriginLab, 2018).</note>
</biblStruct>

<biblStruct xml:id="b69">
	<monogr>
		<title level="m" type="main" xml:id="_8rv9eNh">juicr: automated and manual extraction of numerical data from scientific images</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lajeunesse</surname></persName>
		</author>
		<idno type="DOI">10.32614/cran.package.juicr</idno>
		<imprint>
			<date type="published" when="2021">2021</date>
			<biblScope unit="volume">0</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Lajeunesse, M. J. juicr: automated and manual extraction of numerical data from scientific images v.0.1 (2021).</note>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title level="m" type="main" xml:id="_6nrffbS">R: a language and environment for statistical computing</title>
		<imprint>
			<date type="published" when="2022">2022</date>
			<publisher>R Foundation for Statistical Computing</publisher>
			<biblScope unit="volume">4</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">R: a language and environment for statistical computing v.4.2.2 (R Foundation for Statistical Computing, 2022).</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_QKXzeNN">Classification and regression by randomForest</title>
		<author>
			<persName><forename type="first">A</forename><surname>Liaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wiener</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JK3VbBd">R News</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="18" to="22" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liaw, A. &amp; Wiener, M. Classification and regression by randomForest. R News 2, 18-22 (2002).</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_CXRztVz">Ensemble-based classifiers</title>
		<author>
			<persName><forename type="first">L</forename><surname>Rokach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KYfxQYZ">Artific. Intel. Rev</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1" to="39" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rokach, L. Ensemble-based classifiers. Artific. Intel. Rev. 33, 1-39 (2010).</note>
</biblStruct>

<biblStruct xml:id="b73">
	<monogr>
		<title level="m" type="main" xml:id="_vxXNRTw">emmeans: estimated marginal means, aka Least-Squares Means</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Lenth</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">1</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Lenth, R. V. et al. emmeans: estimated marginal means, aka Least-Squares Means v.1.10.3.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<ptr target="apps.who.int/gho/data/node.main.A900A?lang=en" />
		<title level="m" xml:id="_vZnxqNU">Prevalence of Obesity Among Adults, BMI ≥ 30, Age-Standardized Estimates by Country</title>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2017">2017</date>
		</imprint>
		<respStmt>
			<orgName>Global Health Observatory</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Global Health Observatory. Prevalence of Obesity Among Adults, BMI ≥ 30, Age- Standardized Estimates by Country (World Health Organization, 2017); apps.who.int/gho/ data/node.main.A900A?lang=en.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<monogr>
		<ptr target="www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/population/population-estimates/mid-year-population-estimates/population-estimates-time-series-data" />
		<title level="m" xml:id="_jvHEgWZ">Mid-year Population Estimates: Time Series Data</title>
		<imprint>
			<publisher>National Records of Scotland</publisher>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">National Records of Scotland. Mid-year Population Estimates: Time Series Data (National Records of Scotland, 2022); www.nrscotland.gov.uk/statistics-and-data/statistics/ statistics-by-theme/population/population-estimates/mid-year-population-estimates/ population-estimates-time-series-data.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main" xml:id="_QFQXH7p">The PTPIP51 coiled-coil domain is important in VAPB binding, formation of ER-mitochondria contacts and IP3 receptor delivery of Ca 2+ to mitochondria</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Morotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zxmJJ2c">Front. Cell Dev. Biol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">920947</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Morotz, G. M. et al. The PTPIP51 coiled-coil domain is important in VAPB binding, formation of ER-mitochondria contacts and IP3 receptor delivery of Ca 2+ to mitochondria. Front. Cell Dev. Biol. 10, 920947 (2022).</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v8y7YAX">Mathematica</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2022">2022</date>
			<publisher>Wolfram Research</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Mathematica v.13.1 (Wolfram Research, 2022).</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_ndRs4xD">The incidence and prevalence of paediatric-and adult-onset inflammatory bowel disease in Denmark during a 37-year period-a nationwide cohort study (1980-2017)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Dorn-Rasmussen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zq4Mw3Z">J. Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="259" to="268" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dorn-Rasmussen, M. L. et al. The incidence and prevalence of paediatric-and adult-onset inflammatory bowel disease in Denmark during a 37-year period-a nationwide cohort study (1980-2017). J. Crohns Colitis 17, 259-268 (2023).</note>
</biblStruct>

<biblStruct xml:id="b79">
	<monogr>
		<ptr target="extranet.dst.dk/pyramide/pyramide.htm#!&amp;l=en" />
		<title level="m" xml:id="_CzujAZx">Population 1</title>
		<meeting><address><addrLine>Statbank Denmark</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2023-01">January. 2023</date>
			<biblScope unit="volume">2</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Population 1. January (FOLK2) (Statbank Denmark, 2023); extranet.dst.dk/pyramide/ pyramide.htm#!&amp;l=en.</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main" xml:id="_aGTnWwh">A new relation between prevalence and incidence of a chronic disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Brinks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Landwehr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SnD2Pzt">Math. Med. Biol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="425" to="435" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brinks, R. &amp; Landwehr, S. A new relation between prevalence and incidence of a chronic disease. Math. Med. Biol. 32, 425-435 (2015).</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main" xml:id="_JH5GXN4">Age-specific incidence and prevalence: a statistical perspective</title>
		<author>
			<persName><forename type="first">N</forename><surname>Keiding</surname></persName>
		</author>
		<idno type="DOI">10.2307/2983150</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kF6sUnd">J. R. Stat. Soc</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="371" to="412" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Keiding, N. Age-specific incidence and prevalence: a statistical perspective. J. R. Stat. Soc. 154, 371-412 (1991).</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main" xml:id="_zt7hjwN">Projected number of people with diagnosed Type 2 diabetes in Germany in 2040</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tönnies</surname></persName>
		</author>
		<idno type="DOI">10.1111/dme.13902</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WcZYZwy">Diabet. Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1217" to="1225" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tönnies, T. et al. Projected number of people with diagnosed Type 2 diabetes in Germany in 2040. Diabet. Med. 36, 1217-1225 (2019).</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main" xml:id="_B3UeewZ">Future prevalence of type 2 diabetes-a comparative analysis of chronic disease projection methods</title>
		<author>
			<persName><forename type="first">D</forename><surname>Voeltz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tönnies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brinks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoyer</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0264739</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WT2FMv4">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">264739</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Voeltz, D., Tönnies, T., Brinks, R. &amp; Hoyer, A. Future prevalence of type 2 diabetes-a comparative analysis of chronic disease projection methods. PLoS ONE 17, e0264739 (2022).</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main" xml:id="_hXFMGvE">Life expectancy and healthadjusted life expectancy in people with inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kuenzig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Manuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Donelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Benchimol</surname></persName>
		</author>
		<idno type="DOI">10.1503/cmaj.190976</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tANxWB8">Can. Med. Assoc. J</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page">80</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kuenzig, M. E., Manuel, D. G., Donelle, J. &amp; Benchimol, E. I. Life expectancy and health- adjusted life expectancy in people with inflammatory bowel disease. Can. Med. Assoc. J. 192, E1394-E1402 (2020). 80</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<idno type="DOI">10.1057/msq.2011.26</idno>
		<ptr target="www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710004001" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_K2YbkyP">0040-01 Estimates of the Components of International Migration</title>
		<meeting><address><addrLine>Statistics Canada</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2023">2023</date>
			<biblScope unit="page" from="17" to="27" />
		</imprint>
	</monogr>
	<note type="raw_reference">Table 17-10-0040-01 Estimates of the Components of International Migration, Quarterly (Statistics Canada, 2023); www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710004001.</note>
</biblStruct>

<biblStruct xml:id="b86">
	<monogr>
		<idno type="DOI">10.1163/2213-2996_flg_com_063090</idno>
		<ptr target="www.dst.dk/en/Statistik/emner/borgere/flytninger/ind-og-udvandring" />
		<title level="m" xml:id="_BvEtK7N">Immigration and emigration</title>
		<meeting><address><addrLine>Statbank Denmark</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Immigration and emigration (Statbank Denmark, 2023); www.dst.dk/en/Statistik/emner/ borgere/flytninger/ind-og-udvandring.</note>
</biblStruct>

<biblStruct xml:id="b87">
	<monogr>
		<idno type="DOI">10.18356/9789292686468c006</idno>
		<ptr target="www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/migration/migration-statistics/migration-flows/total-migration-to-or-from-scotland" />
		<title level="m" xml:id="_QPjR7Rg">Total Migration To or From Scotland</title>
		<imprint>
			<publisher>National Records of Scotland</publisher>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Total Migration To or From Scotland (National Records of Scotland, 2023); www.nrscotland. gov.uk/statistics-and-data/statistics/statistics-by-theme/migration/migration-statistics/ migration-flows/total-migration-to-or-from-scotland.</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main" xml:id="_Zq6PqHm">Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Benchimol</surname></persName>
		</author>
		<idno type="DOI">10.1038/ajg.2015.52</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ehPGXCY">Am. J. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="553" to="563" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benchimol, E. I. et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am. J. Gastroenterol. 110, 553-563 (2015).</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main" xml:id="_at4uPFa">Inflammatory bowel diseases among first-generation and secondgeneration immigrants in Denmark: a population-based cohort study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Agrawal</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2020-321798</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Jh8FnMD">Gut</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1037" to="1043" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Agrawal, M. et al. Inflammatory bowel diseases among first-generation and second- generation immigrants in Denmark: a population-based cohort study. Gut 70, 1037-1043 (2021).</note>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title level="m" type="main" xml:id="_kJ6hDQn">Handbook of First Order Partial Differential Equations</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Polyanin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">F</forename><surname>Zaitsev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moussiaux</surname></persName>
		</author>
		<idno type="DOI">10.1201/b16828</idno>
		<imprint>
			<date type="published" when="2002">2002</date>
			<publisher>Taylor &amp; Francis</publisher>
			<biblScope unit="volume">1</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Polyanin, A. D., Zaitsev, V. F. &amp; Moussiaux, A. Handbook of First Order Partial Differential Equations Vol. 1 (Taylor &amp; Francis, 2002).</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main" xml:id="_U4t6ZMB">East-west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort</title>
		<author>
			<persName><forename type="first">J</forename><surname>Burisch</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2013-304636</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_azpF8hc">Gut</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="588" to="597" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burisch, J. et al. East-west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 63, 588-597 (2014).</note>
</biblStruct>

<biblStruct xml:id="b92">
	<monogr>
		<title level="m" type="main" xml:id="_8AjNxjN">Data for &apos;Global evolution of inflammatory bowel disease across epidemiological stages</title>
		<author>
			<persName><forename type="first">L</forename><surname>Hracs</surname></persName>
		</author>
		<idno type="DOI">10.6084/m9.figshare.24952557</idno>
		<ptr target="https://doi.org/10.6084/m9.figshare.24952557" />
		<imprint>
			<date type="published" when="2025">2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hracs, L. et al. Data for &apos;Global evolution of inflammatory bowel disease across epidemiological stages&apos;. Figshare https://doi.org/10.6084/m9.figshare.24952557 (2025).</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
